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Abstract
Abstract
Tumour development is not an entirely cell-autonomous process, being dependent 
on the ability of bystander cells, mostly of bone marrow (BM) origin, to establish a 
pro-tumourigenic microenvironment. We hypothesize that identification of early BM 
changes would confirm that BM senses the onset of a neoplastic lesion in 
peripheral tissues even at very early stages of carcinogenesis and that such 
peripheral alterations could offer the opportunity to identify key signalling 
molecules that may represent early biomarkers of cancerogenesis and could allow 
discovering novel potential therapeutic targets.
To test such hypothesis we took advantage of the MMTV-NeuT (NeuT) transgenic 
mouse model of mammary carcinogenesis and found that profound BM 
modifications in the composition and spatial arrangement of the hematopoietic 
populations, such as increase of immature myeloid granulocytic cells, contraction 
of B lymphoid pools, displacement of BM niches characterize NeuT mice with 
overt carcinomas in comparison to wild-type mice and that such modifications 
were already detectable at earlier stages of carcinogenesis, although less 
significant.
Genes differentially expressed in the BM between transgenic and controls with 
overt tumour have been used to design an ad hoc “late gene signature” that has 
been tested and validated in two additional breast cancer models. Early NeuT BM 
samples already show differentially expressed genes in comparison to controls 
and they are efficiently separated by the late gene signature in two clusters: those 
with normal/mild dysplasia in their mammary glands from those with sever
____________________ Abstract___________________
dysplasia/early carcinomas. Different circulating microRNA profiles characterized 
early stages of tumourigenesis and BM down-regulated genes are among their 
predictive targets.
With an unprecedented level of integration between BM mRNA and microRNA 
profiles, BM immunolocalization, circulating microRNA profile and primary lesion 
histopathology we could demonstrate that the BM is an early sensor of incipient 
mammary tumour and that the alterations observed in advanced carcinomas are, 
at least in part, already present at early stages.
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Introduction
1 Introduction 
1.1 Breast Cancer biology
1.1.1 Mammary gland organization
The adult female breast is composed of epithelial lactiferous ducts terminating in 
secretory alveoli embedded in a complex microenvironment comprised of 
basement membrane, extracellular matrix (ECM) molecules and a variety of 
stromal cell types including adipocytes, fibroblasts, endothelial cells and immune 
cells. The functional unit of the mammary gland is represented by the lobus, which 
is drained by a duct and it is divided into smaller ducts ending with the terminal 
ductal-lobular unit (TDLU). Each TDLU is composed of two kinds of cells 
organized in distinct layers: luminal epithelial cells, expressing CK8, surrounded by 
CK5+ basal myoepithelial cells, lying on the basal membrane (Figure 1).
In response to estrogen, progesterone and other hormones, the developing ducts 
begin to infiltrate into the surrounding stromal tissue, a mechanism that requires 
extensive remodeling of the ECM. This process of ECM remodeling, together with 
proliferation and migration of mammary epithelial cells, is termed branching 
morphogenesis (Lu and Werb 2008). Normal breast growth and development are 
regulated by a complex interaction of many hormones and growth factors such as 
prolactin, thyroid hormone, insulin, insulin-like growth factors (IGF) 1-2, fibroblast 
growth factor (FGF), endothelial growth factor (EGF), transforming growth factor 
alpha (TGF-a) (Sternlicht, Kouros-Mehr et al. 2006).
11
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Figure 1 - Schematic representation o f the mammary gland structure.
A) Pre- and pubertal mammary glands are composed by duct terminating in terminal end buds 
(TEBs); B) in a normal mammary gland alveoli are formed by a single layer of luminal cells 
surrounded by myoepithelial cell and a basement membrane, providing contact with the 
extracellular environment.
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All these molecules can act in an autocrine manner if secreted by mammary cells 
themselves or in a paracrine way when secreted by stromal accessory cells. Such 
cross-talk between the stromal microenvironment and mammary epithelial cells 
actively contributes to direct the mammary gland branching morphogenesis 
(Dickson and Lippman 1995) (Polyak and Kalluri 2010).
Among the most abundant cells present in the mammary gland stroma, adipocytes 
provide not only a scaffold for the branching epithelia, being indispensable for 
development and function of the gland, but also represent a reservoir of 
metabolites and signaling molecules (Hovey and Aimo 2010).
In addition to adipocytes, cells of the immune system have pleiotropic roles in 
mammary gland development. For instance, macrophages promote epithelial cell 
proliferation and chemotaxis, secreting EGF, and are necessary for ductal 
outgrowth (Gouon-Evans, Rothenberg et al. 2000). Mast cells coordinate epithelial 
proliferation and morphogenesis by releasing serine proteases by degranulation 
(Lilia and Werb 2010). Fibroblasts maintain the extracellular environment through 
the production and remodeling of the ECM (Mailer, Martinson et al. 2010) (Arendt, 
Rudnick et al. 2010). The collagen-rich ECM provides the architecture supporting 
gland development and represents a physical barrier that must be remodeled to 
allow the branching of the ducts.
In summary, the cross-talk between multiple cell types within the epithelial and 
stromal compartment of the mammary gland participate in the developmental 
program of the mammary architecture and functionality.
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1.1.2 Breast cancer development and classification
Breast cancer (BC) is the most common cancer in women with the highest 
mortality of any cancer worldwide. As the majority of tumours, BC is really a 
heterogeneous disease, with different pathologic features, biologic behaviour and 
variable response to therapy. Despite these differences a recent study 
demonstrated that most of the malignant lesions arising in the mammary gland 
derive from luminal progenitors (Molyneux, Geyer et al. 2010). The conversion of a 
normal cell of the breast into a neoplastic cell can be due to cell intrinsic changes 
(such as genetic alterations) or cell extrinsic, that could derive to the exposition to 
exogenous environmental factors.
Breast transformation could be due to multiple types of genetic alterations usually 
affecting three classes of genes: (i) oncogenes, genes that lead to malignancy 
only if activated by mutation, enhancement of expression or amplification, (ii) 
tumour suppressor genes, which function has to be lost by either mutation or 
deletion, (iii) modifiers, genes that are involved in DNA repair processes. Mutated 
cells start to proliferate in abnormal way originating a condition called hyperplasia. 
With the accumulation of other mutations, the cells also experience phenotypic 
variations becoming dysplastic then affecting the architecture of the tissue itself, 
losing their differentiation and the contact with other cells. At this stage, called 
carcinoma in situ, proliferation is confined in the tissue of origin, without the 
disruption of the basal membrane integrity that would constitute extension beyond 
epithelial boundaries. During malignant progression additional mutations may 
occur, enabling the tumours to cross the basal membrane invading neighbouring
14
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tissues and to shed cells into the blood or lymphatic system, that spread to distant 
organs and form metastases (Figure 2).
transforming
event
hyperplasia dysplasia carcinoma in situ
invasive
carcinoma
Figure 2  -  Breast cancer development.
Cancer progression starts with a transforming event, usually a mutation, that makes cells more 
likely to divide. Transformed cells begin to grow without control creating a condition called 
hyperplasia. Accumulating other mutations, cells continue with their abnormal proliferation and start 
to change phenotype, originating a state of hyperplasia. In the next steps of tumour development, 
called carcinoma in situ, cells also lose their differentiation and contact, remaining in their epithelial 
layer of origin. The in situ cancer may remain limited or invade neighbouring tissues and shed cells 
into the blood or lymph, becoming a malignant invasive cancer.
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Classification of BC is usually based on the histopathological appearance of the 
tumour tissue and on growth patterns of the tumour. In this way, BCs without 
invasive capacity are classified as hyperplastic lesions or in situ carcinoma. There 
are two main types of in situ carcinoma: ductal carcinoma in situ (DCIS) and 
lobular carcinoma in situ (LCIS), the latter recently considered a lobular neoplasia 
since it does not seem to turn into invasive cancer if left untreated (Simpson, Gale 
et al. 2003). Concerning invasive cancers, the most common are invasive ductal 
(IDC) and invasive lobular carcinomas (ILC) that together account for about 90% 
of invasive BC. Less common invasive tumours include inflammatory BC, a rare 
and aggressive form of locally advanced BC, Paget disease of the breast, a rare 
cancer in the skin of the nipple or closely surrounding it and metaplastic BC that is 
rare and difficult to diagnose. For clinical utility purpose, especially for early-stages 
BC, in order to have a sufficient prognostic and predictive power, a full 
classification should include other parameters such as grade, stage and receptor 
status. The grading of BC depends on the cytological similarity of BC cells to 
normal breast tissue and classifies the cancer as well differentiated (low-grade), 
moderately differentiated (intermediate grade) and poorly differentiated (high 
grade), reflecting progressively less normal appearance of the cells composing the 
tumour; high grade tumours are characterized by a worse prognosis. Moreover, in 
1991, the Nottingham Grading System (NGS) has been introduced in the clinical 
practice becoming the recommended grading system for its prognostic relevance 
(Elston and Ellis 1991). In the NGS, the prognostic index is calculated combining 
lymph node (LN) involvement and tumour size. Finally, the TNM classification for 
staging BC is based on the size of the tumour (T), on tumour spreading to lymph
16
____________________________ Introduction___________________________
nodes (N) and on the presence of distant metastasis (M). In addition, along with 
tumour stage, the expression of hormonal receptors such as estrogen (ER) and 
progesterone (PR) receptors and the human epidermal growth factor receptor-2 
(HER-2) are indicative to further classify BC and to drive the right therapeutic 
approach. These markers allow the classification in three groups: i) ER positive; ii) 
HER-2 overexpressing; iii) triple negative BCs (TNBC) that do not express ER, PR 
and HER-2. Morphologic classification, histologic grade, status of ER, PR and 
HER-2, along with tumour stage, is used to guide clinical management.
1.1.3 Tumour microenvironment
The tumour microenvironment (TME) is recognized as a major regulator of 
carcinogenesis and in BC it is well accepted that the composition of the TME could 
predict both prognosis and therapeutic effect (Denkert, Loibl et al. 2010)(Figure 3). 
As described above, breast tumours evolve via sequential progression through 
defined stages, starting with epithelial hyperplasia and progression to in situ, 
invasive, and metastatic carcinomas. Importantly, the cells infiltrating the tumour 
microenvironment have been implicated in each of these steps of cancer 
progression (Hanahan and Weinberg 2011). Carcinoma-associated fibroblasts 
(CAFs) have been demonstrated to have a role in promoting tumour progression. 
Accordingly, it has been shown that co-culture of normal mammary fibroblasts with 
BC cells can change their phenotype giving them the capability to secrete HGF, 
thus increasing tumour progression (Xing, Saidou et al. 2010) (Tyan, Kuo et al.
2011).
17
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Figure 3 -  The tumour microenvironment
The tumour microenvironment comprises tumour cells but also normal epithelial cells, cells of 
mesenchymal origin such as pericyte and fibroblasts, endothelial cells and different bone marrow- 
derived cells. Presence of heterogeneous cells and their secreted soluble factors, signaling 
molecules, extracellular matrix and mechanical cues with in the tumour m icroenvironment 
promote neoplastic transformations, support tumour growth and invasion.
From Cancer Research Reviews 2012 AACR
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It seems that CAFs may originate from the differentiation of bone marrow (BM)- 
derived mesenchymal stem cells and be recruited to the tumour site by molecules 
produced by tumour cells themselves. This evidence supports the hypothesis that 
tumour-derived signals can induce modifications in the BM able to stimulate the 
generation and differentiation of cells with tumour promoting capacity (Direkze, 
Jeffery et al. 2006) (Shin, Nam et al. 2010). Also, BM-derived immune cells 
represent one of the most dynamic cell population within tumour microenvironment 
with both tumour promoting and inhibiting activities (Coussens and Werb 2002). 
For example, tumour-associated macrophages (TAM) have been shown to play a 
role in BC progression increasing angiogenesis, ECM degradation and 
consequently tumour invasion through different mechanisms (Schedin, O'Brien et 
al. 2007). Moreover, high numbers of infiltrating leukocytes are present in DCIS 
with focal myoepithelial cell layer disruptions (Man and Sang 2004), suggesting 
that they might play a role in invasive progression. Also, CD4+ forkhead box P3 
(FOXP3+) T regulatory cells, CD4+T helper 2 (Th-2) cells, M2 macrophages and 
myeloid-derived suppressor cells (MDSCs) may promote tumour growth (Emens
2012).
Conversely, cytotoxic CD8+ T cells can exploit anti-tumour activity through 
different mechanism of recognition of cancer cells such as via major 
histocompatibility complex (MHC) class I, FAS and tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) receptor. CD4+ T cells contribute to tumour 
eradication by the secretion of pro-inflammatory cytokines such as IL-2, IFN-y and 
TNF-a that, together, promote the establishment of a type-1-like inflammation
19
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environment that promote tumour eradication. Some of the mechanisms by which 
these subsets affect tumour growth are shown in Figure 4.
Moreover, tumour cells are able to suppress tumour-infiltrating lymphocytes (TILs) 
either through direct suppression or through the recruitment and reactivation of 
immunosuppressive subsets.
One of these mechanisms of suppression involves the expression of ligands for 
checkpoint inhibitors such as CTLA-4 and PD-1 by tumour cells that triggers the 
inhibitory pathways on TILs (Wolchok and Chan 2014). For example, the 
expression of PD-L1 on tumour cells, induces anergy/apoptosis of PD-1+ CD8+ T 
cells, halting the host antitumour immune responses (Pardoll 2012). Accordingly, 
both PD-1 and CTLA-4 blockade have been proven to be very effective, not only in 
preclinical animal models (van Elsas, Hurwitz et al. 1999, Fan, Quezada et al. 
2014, Kim, Skora et al. 2014, Pentcheva-Hoang, Simpson et al. 2014), but also in 
clinical practice. Indeed, an increasing number of studies are showing positive 
results for such immune checkpoint blockers, at least in some tumour histotypes 
(Brahmer, Drake et al. 2010, Wolchok, Neyns et al. 2010, Postow, Callahan et al. 
2015).
In addition to the cellular components of the tumour stroma, also the ECM of BC, 
markedly abnormal, has been shown to promote tumour progression. For 
example, matrix metalloproteinases (MMPs) are a large family of endopeptidases, 
which are synthesized predominantly by fibroblasts and normally participate in 
tissue remodelling and wound healing.
20
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Figure 4 - Pro- and anti-tumour immune response in breast cancer.
The antitumour immune response depends on IFNy produced by CD4+ T cells responsible of the 
expansion, differentiation, and activation of tumour-specific CD8+ cytotoxic T cells. CD8+ T cells are 
able to recognize tumour associated antigens thus inducing lysis of the cells. Similarly, CD4+ T 
cells recognize MHC II on antigen presenting cells. The reults of these interactions is the release of 
granzymes, IFNy, and perforin from these cytotoxic lymphocytes resulting in granule exocytosis 
and tumour cell death via apoptosis. Also, NK and NKT cells are able to recognize and eliminate 
tumour cells.
In contrast, a protumoural immune response results by inhibitory signals delivered by CTLA-4, TIM- 
3 and PD-1 as a consequence of T cell exhaustion. Also, FOXP3+ Treg cells play a critical role 
during the selection of high-avidity CD8 + T cells, reducing their functionality. Tumour cells can 
secrete cytokines and chemokines (e.g., TGF-p, CCL2) that recruit and stimulate suppressive cells 
such as Tregs, MDSCs, and M2 macrophages. M2 macrophages and MDSCs inhibit T-cell 
responses through nutrient sequestration via arginase, ROS, and NOS generation, as well as 
interference with trafficking into the tumour site. Tregs exert their inhibitory action on APCs, CD8+ T 
cells, NKs, and CD4+ Th1 T cells.
From Dushyanthen S. BMC Med. 2015
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Besides degrading ECM components, MMPs can also activate chemokines, 
cytokines, adhesion molecules, and growth factors, which contribute to tumour 
progression by increasing tumour cell proliferation (e.g. the release of IGF from 
ECM by MMP3 and -7) or by promoting angiogenesis (e.g., activation of 
angiogenic factors by MMP1, -2, -9, and -14) (Chabottaux and Noel 2007).
In addition, abnormal physical characteristics of transformed breast tissue, such as 
irregular collagen cross-linking that results in ECM stiffening, contribute to tumour 
progression. In this context, a central role is played by lysyl oxidases (LOX), amine 
oxidases commonly expressed in breast cancer, which promote collagen cross- 
linking and enhances ECM stiffening. Accordingly, their inhibition in the MMTV- 
Neu model of BC increases tumour latency and decreases tumour burden 
(Levental, Yu et al. 2009). Moreover, the elevated expression of lysyl oxidase-like 
2 is associated with worse prognosis in early stage ER-negative BCs (Barker, 
Chang et al. 2011).
1.1.4 Gene expression data in breast cancer
Although the current well-established clinical, histological and biological factors 
show strong association with prognosis, there is increasing evidence that these 
variables would not be sufficient to tailor the therapy to individual patients. The 
introduction of high-throughput technologies, coupled with powerful analytic tools, 
has redefined the classification of BC into biologically and clinically different 
groups based on gene expression patterns (Sorlie, Tibshirani et al. 2003, Sotiriou, 
Neo et al. 2003) and DNA copy alterations (Chin, DeVries et al. 2006).
22
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Perou (Perou, Sorlie et al. 2000) and Sorlie (Sorlie, Perou et al. 2001) identified 
the so-called intrinsic subtype of BC, namely luminal A, luminal B, HER2-enriched, 
basal-like and normal breast-like. These subsets are associated with different risk 
to relapse and to response to therapy (Ribelles, Perez-Villa et al. 2013, Prat, Fan 
et al. 2015, Prat, Pineda et al. 2015) (Figure 5).
Subsets defined with histological criteria share similarities with intrinsic subtypes 
even though they are not identical. In particular, the molecular subtypes generally 
categorize with the receptor status. The ER+ broad group contains luminal A and 
luminal B tumours (ER+PR+HER2- and ER+PR+HER2+, respectively), which 
express luminal CK8/18 and genes associated with an active ER pathway. The 
ER-negative group includes at least 3 subtypes: normal breast-like, HER2 and 
basal-like. HER2-enriched tumours do not express hormonal receptors but 
overexpress HER2 and genes associated with the HER2 pathway. Basal-like 
tumours express genes usually found in normal basal/myoepithelial cells, including 
basal cytokeratins 5/17, nestin and EGFR. The HER2 and the basal-like subtypes 
have an aggressive clinical behavior. Most of basal-like tumours are triple negative 
breast cancers (TNBC) that do not express hormonal receptors or HER2 and 
account from 10-15% of all breast carcinomas. They represent an aggressive 
histological group, with very poor prognosis, as they do not respond to endocrine 
therapy or therapies targeting the HER2 receptor.
Although the Sorlie’s intrinsic subtypes have set the standard for classification, 
several other molecular studies with varying numbers of genes included in the 
signature, allowed other classifications. For instance, Sotiriou et al. identified six
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groups of BCs, which include three luminal-like, one HER2-enriched and two 
basal-like subtypes (Sotiriou, Neo et al. 2003).
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Figure 5  -  Breast cancer intrinsic subtypes
A) Schematic view of breast cancer subtypes on the bases of gene expression patterns and 
relative presence of hormonal receptor in each subtype. B) Correlation of the intrinsic subtypes with 
the overall survival (OS) in human breast cancer patients.
Modified and adapted from from Sorlie et al. PNAS 2001 and Perou et al. Nature 2000
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Fan et al. have suggested a 70-gene signature to classify tumours in four groups 
(Fan, Oh et al. 2006). Notably, Parker e al. reported a 50-gene classifier (PAM50), 
which mostly contains hormone receptor- and proliferation-related genes, and 
genes associated with myoepithelial and basal features. PAM50 signature has 
significant prognostic and predictive values in BC and is actually being applied in 
the clinical setting (Parker, Mullins et al. 2009, Gnant, Filipits et al. 2014) (Figure 
6).
All these data have been obtained performing gene expression profiles in tumour 
specimens or cancer cells, but the well-established concept that tumour- 
associated stroma is activated by malignant epithelial cells to foster tumour 
growth, prompted several research groups to better understand the interactions 
between epithelial and stromal components of BC at the molecular level. Tumour 
microenvironment-related genes may indeed provide novel targets for diagnostic 
development and therapeutic intervention. Allinen and colleagues, performing the 
first systematic profiling of different tumour infiltrating stromal cells, demonstrated 
that gene expression alterations in all cell types within the tumour 
microenvironment go along with progression from normal breast tissue to DCIS 
and to IDC, providing evidence that these cell types participate in tumourigenesis 
(Allinen, Beroukhim et al. 2004). In particular, many of the genes involved in 
normal myoepithelial cell differentiation and function are downregulated in DCIS- 
associated myoepithelial cells, whereas genes that promote tumourigenesis are 
increased. Taking in the consideration this aspect, Ma and co-workers firstly 
discovered that most of the gene expression changes take place prior to local 
invasion to IDC (Ma, Salunga et al. 2003), and then extended the analysis to the
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tumour stromal and demonstrated that, not only the tumour epithelium, but also the 
tumour stromal microenvironment undergoes extensive gene expression 
alterations during the transition from normal to pre-invasive stage of DCIS before 
IDC occurs (Ma, Dahiya et al. 2009).
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Figure 6 -  Prognostic and predictive value of PAM50 signature.
Prognosis for relapse-free survival (RFS) of PAM50 intrinsic subtypes of breast cancer are 
described. (A) Outcome predictions according to Luminal A and B, HER2-enriched and basal-like 
subtypes in a test set of 710 patients with put lymphnode involvement and without systemic 
adjuvant therapy; (B) outcome by subtype in the same subset of patients with estrogen receptor 
(ER) -positive or negative (C) disease; (D) outcome by subtype in HER2-positive patients.
From Parker JS. J Clin Oncol. 2009
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1.1.5 microRNAs
MicroRNAs or miRNAs are small (~22 nucleotides), evolutionary conserved, 
single-stranded, non-coding RNA molecules that bind mRNA targets to prevent 
their translation into proteins by distinct mechanisms. The biogenesis of 
microRNAs is tightly controlled in a step-by-step sequence of events and their 
deregulation is associated with many diseases, particularly cancer.
The majority of microRNA genes are transcribed by RNA polymerase II (Pol II) in 
the nucleus, where primary microRNAs (pri-microRNAs) are capped, spliced and 
polyadenylated (Lee, Kim et al. 2004). A pri-microRNAs can either give origin to a 
single microRNA or contain clusters of two or more microRNAs that are processed 
from a common primary transcript. The synthesis of mature microRNAs from pri- 
microRNAs occurs in two stages and it is catalyzed by two RNAse Ill-type proteins 
namely Drosha and Dicer. Drosha processes the pri-microRNA in the nucleus to a 
precursor microRNA (pre-microRNA) (Lee, Ahn et al. 2003), then transported to 
the cytoplasm by exportin-5 (XP05) (Yi, Qin et al. 2003). In the cytoplasm, pre- 
microRNA are further processed to become mature microRNAs by Dicer (Park, 
Heo et al. 2011) and loaded on to the Argonaute (ago) protein to produce the 
effector RNA-induced silencing complex (RISC) (Kim, Han et al. 2009). The 
microRNA acts as a guide by base-pairing with target mRNA to negatively regulate 
its expression. The microRNA-mRNA interactions occur between the seed 
sequence of the microRNA, defined as the first 2-8 nucleotides from the 5’ toward 
the 3’, and the 3’ untranslated region (3’ UTR) of the mRNA.
The level of complementarity between the guide and the target mRNA determines 
which silencing mechanism will be employed: cleavage of target mRNA with
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subsequent degradation or inhibition of its translation (Perron and Provost 2008) 
(Bartel 2004) (Figure 7).
Considering that a single microRNA can target hundreds to thousands different 
mRNAs, and that a mRNA can be coordinately suppressed by multiple different 
microRNAs, these small RNAs control almost every biological process (Krek, Grun 
et al. 2005).
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Figure 7 -  microRNA biogenesis
MicroRNA (miRNA) genes are transcribed as primary miRNAs (pri-miRNAs) by RNA polymerase II 
(Pol II) in the nucleus. The long pri-miRNAs are cleaved by Microprocessor, which includes 
DROSHA and DiGeorge syndrome critical region 8 (DGCR8), to produce the 60-70-nucleotide 
precursor miRNAs (pre-miRNAs). The pre-miRNAs are then exported from the nucleus to the 
cytoplasm by exportin 5 (XP05) and further processed by DICER1, a ribonuclease III (Rill) enzyme 
that produces the mature miRNAs. One strand of the mature miRNA (the guide strand) is loaded 
into the miRNA-induced silencing complex (miRISC), which contains DICER1 and Argonaute 
(AGO) proteins, directs the miRISC to target mRNAs by sequence complementary binding and 
mediates gene suppression by targeted mRNA degradation and translational repression in 
processing bodies (P-bodies). TRBP, transactivation-responsive RNA-binding protein.
From Lin and Gregory Nat Rev Cancer. 2015
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1.1.6 Role of microRNAs in breast cancer
Recently, the definition of oncogenes and tumour suppressors has been expanded 
from the classical protein coding genes to include also microRNAs (Garzon, Fabbri 
et al. 2006, Wu, Sun et al. 2007), however their specific classification in these two 
categories can be difficult due to the complex expression patterns of microRNAs 
that differ from tissue to tissue (Lagos-Quintana, Rauhut et al. 2002, Lu, Getz et al. 
2005, Lee and Dutta 2007, Mayr, Hemann et al. 2007). Indeed, it is not clear 
whether altered microRNA patterns could be considered a direct cause of cancer 
or rather and indirect effect of changes in the phenotype of the cells composing a 
transforming tissue. In addition, tissue specific expression could implicate that a 
single microRNA can act as a tumour suppressor in one context and as an 
oncogene (oncomiR) in another one.
What is now clear is that microRNAs may play roles in different steps of breast 
tumourigenesis, starting from tumour cell proliferation and differentiation to more 
advanced phases such as metastatic invasion (Goh, Loo et al. 2016).
Recent evidences have revealed that microRNAs are deregulated during cancer 
progression (McManus 2003, Meltzer 2005, Esquela-Kerscher and Slack 2006); 
accordingly, genome-wide studies demonstrated that microRNA genes are 
frequently located at cancer-associated genomic regions or in fragile sites. For 
example, downregulation of microRNAs is frequently observed in transformed 
tissue (Calin, Sevignani et al. 2004, Yanaihara, Caplen et al. 2006) suggesting a 
tumour suppressive role for down-regulated microRNAs in this setting. 
Nevertheless, because the abrogation of differentiation is considered a hallmark of 
cancer, the low-level expression of such microRNAs may be related to the state of
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poor differentiation of cancer cells. If so, the expression of these microRNAs would 
be up-regulated when the cancer cells are induced to differentiate (Lu, Getz et al. 
2005).
On the other side, up-regulation of microRNAs is frequently observed in different 
types of cancer, either haematological or solid tumours (Calin, Liu et al. 2004, Eis, 
Tam et al. 2005, Volinia, Calin et al. 2006). In BC, oncomiRs mostly affect 
proliferation of cancer cells and metastasis, and very few oncomiRs are known to 
be involved in angiogenesis and evasion of apoptosis (Figure 8).
Examples of breast oncomiRs are miR-10b, miR-21, miR-155, miR-373 and miR- 
520c (Figure 9). miR-10b targets homeobox 10 (HOXD10) a protein with a DNA 
binding domain, thereby promoting cell migration and invasion (Ma, Teruya- 
Feldstein et al. 2007, Tang, Ahmad et al. 2012). miR-21 has been reported to be 
associated with invasive and metastatic BC (Huang, Wu et al. 2009) mediating cell 
survival, proliferation, extravasation (lorio, Ferracin et al. 2005) and regulating 
EMT and hypoxia-inducible factor 1-alpha (HIF1A) in BC stem-like cells (Han, 
Wang et al. 2012). Up-regulation of miR-155 has been shown to increase 
proliferation of the MCF7 breast cancer cell line (Zhang, Zhao et al. 2013). Finally, 
cell migration, invasion and metastases are associated with the expression of 
microRNA-373 and -520c, which act targeting the cell surface antigen CD44 
involved in cell-cell adhesion (Huang, Gumireddy et al. 2008, Yan, Xu et al. 2011).
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Figure 8 -  Breast cancer-related microRNAs
Different miRNAs affecting the hallmarks of breast cancer. Oncogenic miRNAs and tumour 
suppressor miRNAs in breast cancer cells are shown in red and green, respectively
From Kaboli et al. Pharmacol res 2015
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Among tumour-suppressor microRNAs, miR-125b, miR-205, miR206 and miR-17- 
92 cluster have been show to have a role in BC. Specifically miR-125b targets 
erythropoietin as well as ERBB2 and is one of the most down-regulated microRNA 
in BC (Scott, Goga et al. 2007, Ferracin, Bassi et al. 2013); miR-205 is able to 
inhibit cell proliferation and promote apoptosis (Elgamal, Park et al. 2013, Liu, Mao 
et al. 2013); miR-206 inhibits cell proliferation, migration and invasion by targeting 
cyclin D2 (Li, Hong et al. 2013) and Jiang and colleagues revealed that the 
expression of miR-17-92 cluster in TNBC was associated with significantly 
reduced metastasis (Fan, Sethuraman et al. 2014, Jiang, Wang et al. 2014) 
(Figure 9).
These results have been obtained thanks to new advances in technology that 
have permitted to improve the accuracy, specificity and feasibility of microRNA 
profiling, from glass slide microarrays (Babak, Zhang et al. 2004, Sun, Koo et al. 
2004) to bead-based flow cytometry and bead-arrays. All these techniques 
allowed the identification of microRNA expression patterns that characterize the 
presence of a state of disease, distinguishing between subtypes of normal and 
malignant tissues (Lu, Getz et al. 2005). MicroRNA signature profiles have been 
demonstrated to have a prognostic significance (Yanaihara, Caplen et al. 2006), to 
predict response to therapy (Meng, Henson et al. 2006) and treatment efficacy 
(Miller, Ghoshal et al. 2008), but also patient susceptibility to cancer and 
occurrence of metastasis (Calin, Ferracin et al. 2005, Ma, Teruya-Feldstein et al. 
2007).
In addition, recent studies have found stable microRNAs not only in tumour tissues 
but also in readily available body fluids including serum, plasma, urine and saliva.
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Indeed, a great effort has been put in the application of microRNAs as new 
circulating biomarkers for early diagnosis, prognosis or prediction of response to 
therapy in tumours (Wang and Chen 2014, Cheng 2015).
In the context of early diagnosis, a microRNA-based signature has been found to 
discriminate between early stage of BC and healthy controls (Kodahl, Lyng et al. 
2014). Chan and colleagues (Chan, Liaw et al. 2013) identified four microRNAs 
(miR-1, miR-92a, miR133a and miR-133b) as significant diagnostic markers in 
serum samples of BC patients. Another group of four up-regulated microRNAs 
(miR-148b, miR-376c, miR409-3p and miR-801) in plasma of BC was found to be 
able to discriminate between stage I and II BC (Cuk, Zucknick et al. 2013). A 
prospective study identified three microRNAs significantly up-regulated only in 
serum of women who developed BC and not in healthy women (Godfrey, Xu et al.
2013) (Figure 10).
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microRNA Target Function
miR-lOb
miR-21
miR-155
miR-373
miR-520c
HOXDIO Promotes cell migration, invasion and metastasis
PDCD4, HIF1A Promotes invasion, metastasis, migration and EMT
SOCS1 Promotes cell growth and proliferation
TP53INP1 Promotes proliferation
F0X03 Promotes proliferation and survival
CD44 Promotes cell migration, invasion and metastasis
CD44 Promotes cell migration, invasion and metastasis
microRNA Target Function
miR-125b EPO, EPOR, ERBB2 Inhibits cell proliferation, differentiation, migration and invasion
miR-205 HM6B3 Suppresses proliferation and invasion
mR-17-92 Mekk2 Promotes NK cell antitumoral activity and reduces metastasis
miR-206 Cyclin D2, Cx43 Reduces migration, invasion and metastasis
miR-200 ZEB1/2, SNAI1/2 Reduces tumor growth, metastasis and EMT
miR-146b NFkB, STAT3 Reduces survival and metastasis
miR-126 IGFBP2, MERTK, PITPNC1 Reduces metastasis and angiogenesis
miR-335 S0X4, TNC Suppresses metastasis and migration
miR-31 RhoA Inhibits invasion and metastasis
Figure 9 -  OncomiRs and tumour-suppressor microRNAs
A) List of major oncogenic microRNAs in breast cancer. EMT, epithelial-to-mesenchymal transition; 
F0X 03, forkhead box protein 03; HIF1A, hypoxia-inducible factor-1 a; HOXD10, homeobox D10; 
miRNA, microRNA; PDCD4, programmed cell death protein 4; PTEN, phosphatase and tensin 
homolog; S0CS1, suppressor of cytokine signaling 1; TIMP3, metalloproteinase inhibitor 3; TM1, 
tropomyosine 1; TP53INP, tumour protein p53 inducible nuclear protein. B) List of major tumour 
suppressive microRNAs in breast cancer. CCNJ, cyclin J; CK2-a, casein kinase 2-alpha; Cx43, 
connexin 43; ENPEP, glutamylaminopeptidase or aminopeptidase A; EPO, erythropoietin; EPOR, 
erythropoietin receptor; ERBB2, Receptor tyrosine-protein kinase erbB-2 (human epidermal growth 
factor receptor 2); HMGB3, high-mobility group box 3 gene; IGFBP2, insulin-like growth factor- 
binding protein 2; MEGF9, multiple EGF-like domains 9; Mekk2, mitogen-activated protein kinase 
kinase kinase 2; MERTK, c-Mer tyrosine kinase; miRNA, microRNA; NFkB, nuclear factor kappa B; 
NK, natural killer; PITPNC1, phosphatidylinositol transfer protein, cytoplasmic 1; RhoA, Ras 
homolog gene family; SNAI1/2, snail family zinc finger 1/2; S0X4, SRY-related HMG-box 4; 
STAT3, signal transducer and activator of transcription 3; TNC, tenascin C; WAVE3, WAS protein 
family, member 3; ZEB1/2, zinc finger E-box binding homeobox Vz
From Eleni van Schooneveld Breast cancer research 2015
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microRNA_______ Expression (BC vs normal) Sample type
miR-15 Upregulated Serum
miR-18a Upregulated Serum
miR-107 Upregulated Serum
miR-425 Upregulated Serum
miR-133a Downregulated Serum
miR-139-5p Downregulated Serum
miR-143 Downregulated Serum
miR-145 Downregulated Serum
miR-365 Downregulated Serum
miR-155 Upregulated Serum
miR-1 Upregulated Serum
miR-133a Upregulated Serum
miR-133b Upregulated Serum
miR-92a Upregulated Serum
miR-148b Upregulated Plasma
miR-376c Upregulated Plasma
miR-409-3p Upregulated Plasma
miR-801 Upregulated Plasma
miR-16 Upregulated Plasma
miR-21 Upregulated Plasma
miR-451 Upregulated Plasma
miR-145 Downregulated Plasma
miR-18a Overexpressed* Serum
miR-181a Overexpressed* Serum
miR-222 Overexpressed* Serum
Figure 10 -  Circulating microRNAs in breast cancer patients
List of major diagnostic microRNA signatures for the early diagnosis of breast cancer.
From Eleni van Schooneveld Breast cancer research 2015
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1.2 Mouse models of luminal breast cancer
Most of the knowledge about BC etiopathogenesis has been obtained taking 
advantage of mouse models spontaneously developing the disease. Although 
animal models reflect only in part the complex scenario of human diseases, they 
have deeply contributed in understanding the mechanisms driving BC 
pathogenesis.
As in BC patients the amplification of the HER2 gene and its overexpression at the 
messenger RNA or protein level occurs in about 20-30% of cases (Slamon, Clark 
et al. 1987), many of the most widely used animal models of breast carcinogenesis 
rely on the expression of HER2 in the mammary epithelium. In transgenic mouse 
models overexpressing HER2, mammary tissue transformation, in addition to the 
HER2 gene amplification, requires other genetic alterations (such as point 
mutations, deletions and insertions) (Siegel and Muller 1996), reflecting the clinical 
setting.
HER2, also known as ErbB2 or neu in rat, belongs to the epidermal growth factor 
receptor (EGFR) family, which also includes HER1 (EGFR, ErbB1), HER3 (ErbB3) 
and HER4 (ErbB4). HER2 is a 185-kd transmembrane receptor with an 
extracellular binding domain and a long cytoplasmic domain with tyrosine kinase 
activity. The extracellular domain is about 630 amino acids long and contains four 
subdomains arranged as a tandem repeat of a two-domain unit (Cho, Mason et al. 
2003).
Although HER2 is the only receptor of the family without a known ligand, it is the 
preferred partner in heterodimer formation with other HER members, in particular 
HER3.
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Binding of a ligand to the extracellular region of an EGFR family receptor induces 
its dimerization and activation of the cytoplasmic kinase, events that in turn lead to 
autophosphorylation and subsequent downstream signalling events. Intracellular 
signalling pathways activated include the mitogen-activated protein kinases 
(Ras/Raf/MEK/MAPK) pathway and the phosphoinositide 3-kinase (PI3K)- 
activated Akt (PI3K/Akt) pathway, responsible for cell proliferation and survival, 
respectively (Wieduwilt and Moasser 2008).
Her2 is expressed at low levels in normal tissues and it increases not only in 
breast but also in many other transformed tissues such as ovarian, prostate, 
gastric, colorectal, pancreatic, and lung (Hynes and Stern 1994).
In the MMTV-NeuT animal model, neoplastic transformation of the mammary 
epithelium occurs due either to the overexpression or activated form of rat 
HER2/neu (rHER2/neu), which transduces proliferative signals. rHER2/neu 
transgenic BALB/c females, NeuT mice, start to over express the product of the 
rHER-2/neu oncogene at early stages of mammary gland development and under 
hormone pressure during puberty. The tropism for the mammary epithelium is due 
to the presence of the mouse mammary tumour virus (MMTV) promoter, which 
allows the transformation only in this tissue with 100% penetrance. NeuT 
transgenic females develop mammary carcinomas with a well-defined progression, 
beginning at 3-5 weeks with a hyperplasia, condition in which epithelial cells start 
proliferating although the fat pads and the ductal structures are still evident. Then 
hyperplasia becomes atypical characterized by a proliferation of relatively uniform 
population of round epithelial cells assuming a stratified appearance with no 
formation of epithelial bridges. Starting with an occlusive growth of the epithelial
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cells, dysplastic lesions degenerate into carcinoma in situ at around 15 weeks of
age in which the ductal and acinar outlines remain distinct and separate from one
another, with the persistence of intervening stroma. At nearly the 20th week
alveolar groups of neoplastic cell with no myoepithelial lining infiltrate the
surrounding adipose tissue. This feature is distinctive of invasive carcinoma. At
around 30 weeks of age all mammary glands present palpable carcinoma
(Quaglino, Mastini et al. 2008). Morphological examination of mammary neoplasia
in NeuT mice indicates a lobular carcinoma of alveolar type very similar to human
pathology, due to the preferential expression of HER2/neu products in the
epithelium of lobular ducts and lobules. The transition form lobular hyperplasia to
overt carcinoma is associated with a high epithelial proliferation rate and by
activation of tumour angiogenic processes (Di Carlo, Diodoro et al. 1999).
An alternative splice form of the human HER2 gene, huHER2A16, has been
detected in breast carcinomas and reported to comprise 4-9% of total HER2
transcripts (Kwong and Hung 1998). huHER2A16, which forms stable
homodimers, has an increased transforming potency compared to wild-type HER2
form and its ectopic expression significantly enhanced in vitro the proliferation,
migration and invasion of human MCF-7 breast tumour cells (Mitra, Brumlik et al.
2009). In vivo analyses showed that the huHER2A16 variant is tumourigenic perse
and huHER2A16 mice, harbouring an in frame deletion of exon 16, develop
multifocal mammary tumours with a rapid onset, higher incidence and shorter
latency in comparison to MMTV-wtHER2 transgenic model (Castagnoli, lezzi et al.
2014). Castiglioni et al. proposed a causal role of A16HER-2 in cancer
development suggesting that malignant transformation occurs once the proportion
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of A16HER-2 splice variant expression reaches a specific threshold. Conversely, 
wild-type HER-2 is not considered sufficient to induce transformation (Castiglioni, 
Tagliabue et al. 2006), suggesting that the huHER2A16 splice variant represents 
the transforming form of the HER2 oncoprotein (Marchini, Gabrielli et al. 2011). 
Mitra et al. reported that 89% of patients with HER-2-positive breast tumours and 
disease progression to local lymph nodes, expressed A16HER2 (Mitra, Brumlik et 
al. 2009). Measurement of this variant may also be informative in predicting 
response to treatment with anti-HER-2 therapies Indeed, several studies have 
linked A16HER-2 with resistance to trastuzumab advocating the use of tyrosine 
kinase inhibitors as an alternative therapeutical approach (Castiglioni, Tagliabue et 
al. 2006, Mitra, Brumlik et al. 2009).
The A16HER2 variant activates multisignaling cascades including consistent 
phosphorylation of SRC kinase, which aberrant expression and activation occur in 
several tumour types and has been correlated with poor outcome (Guarino 2010). 
SRC is reported to be a driver of trastuzumab resistance and it is found to be 
highly expressed in primary breast tumours, with elevated levels of A16HER2 
transcript, treated with trastuzumab-based regimens in adjuvant setting (Zhang, 
Huang et al. 2011). These tumours are initially dependent on HER2 and are 
responsive to trastuzumab and their progression leads to accumulation of genetic 
alterations that results in lower HER2 dependency and lower responsiveness to 
trastuzumab (Castagnoli, lezzi et al. 2014). This lead to the idea that HER2 
signaling-dependent tumours benefit from trastuzumab at early stages while in 
metastatic setting may escape from trastuzumab therapeutic effects.
Another widely used mouse model of mammary carcinogenesis is the polyoma
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middle T (PyMT) model in which the tumour development is driven by the 
expression of polyoma virus middle T antigen under the control of MMTV 
promoter. Even though human breast tumour cells do not express the PyMT 
protein, the expression of this protein induces cancer development acting on 
several molecules such as Src, ras and PI3K that are often altered in human BC. 
Moreover, the expression of PyMT is associated with an increase in c-myc 
expression, a gene located in one of the three amplified chromosomal regions 
found in human primary BC, rendering the progression of PyMT model strictly 
similar to the women pathogenesis (Lin, Jones et al. 2003).
Premalignant lesions in PyMT mice involve the nipple-proximal terminal end bud 
located at the end of immature ducts surrounding the main collection duct and 
develop at early age, around 4-6 weeks of age. After prepubertal growth, new 
lesions arise in more distal locations, in a ER-dependent manner. Nevertheless, 
along with tumour progression, the distribution of focal atypical lesions along the 
ducts displays a gradient, with more numerous and larger lesions closer to the 
nipple than the other end of the ducts (Maglione, Moghanaki et al. 2001). Indeed, 
the nipple-proximal lesion is the area of origin of the tumour, developing in four 
principal stages similar to human tumours, namely hyperplasia, 
adenoma/mammary intraepithelial neoplasia (MIN), carcinoma in situ, and invasive 
carcinoma.
With the occurrence of advanced premalignant lesions, namely adenomas or 
mammary intraepithelial neoplasia (MIN), the single layer of myoepithelial cell 
starts to be incomplete in many points, only the laminin-1 expressing basement 
membrane remains intact. These preneoplastic lesions are characterized by
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proliferation in the lumen of cells with cytological defects in the nucleus 
morphology.
At later time points, the phases of early and late carcinoma, laminin-1 start to be 
expressed in a scattered manner because of the loss of the acinar structure of the 
ducts and of the myoepithelial layer. An increase in vessels density also favours 
the infiltration of the tumour by immune cells (Lin, Jones et al. 2003). Tumour 
progression is associated with the loss of hormonal receptors, ER and PR, 
expression, a feature that distinguish mice tumours from tumours developing in 
women, which in many cases retain hormonal receptors expression.
Moreover, cyclin D1 increases in its expression whereas integrin beta-1 increases 
at early stages to decline later on. MMTV-PyVMT mammary tumours are enriched 
in proteases, including the MMPs, which are important not only for tissue 
remodelling but also for metastatization that occurs predominantly to the lung in 
this model of carcinogenesis.
1.3 Bone marrow and haematopoiesis
The bone is not only a supporting scaffold for the organism, but it represents an 
organ capable of fine-tuning immunity as it contains, within its cavity, the bone 
marrow (BM), which is the major site of haematopoiesis and bone formation. 
Haematopoiesis is the process by which all mature blood cells are produced. 
Blood development in vertebrates involves two waves of haematopoiesis: the 
primitive and the definitive wave (Galloway and Zon 2003). The primitive wave, 
which involves eryhtroid progenitor cells, occurs in the embryo and it is a transitory 
phenomenon. Definitive haematopoiesis, by contrast, occurs later in development
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and involves hematopoietic stem cells (HSCs), which are multipotent and can give 
rise to all blood lineages of the adult organism. In vertebrates, HSCs are 
generated in a specific region of the developing embryo and they migrate to the 
fetal liver and then to the BM, which is the location for HSCs in adults (Cumano 
and Godin 2007).
BM comprises two principal components: the vascular-stromal area where 
multipotential non-hematopoietic progenitor cells are located, and the 
hematopoietic parenchyma, mainly composed of HSCs and uncommitted 
hematopoietic progenitors (Kopp, Avecilla et al. 2005).
Lambersten and Weiss proposed a model to subdivide the different areas in the 
BM and, starting from the bone surface, they defined the endosteal, subendosteal, 
central and perisinusoidal niches (Figure 11)(Lambertsen and Weiss 1984). 
Multipotential non-hematopoietic progenitor cells or mesenchymal stem cells 
(MSCs), residing in the BM stroma, are able to differentiate into different tissue of 
mesenchymal origin such as osteoblasts, endothelial cells, reticular cells, 
fibroblasts and adipocytes, and are assembled in an organized network to 
physically and biologically support haematopoiesis. For instance, osteoblasts, 
endothelial cells, MSCs and CXCL12-abundant reticular (CAR) cells produce 
several factors to support HSCs, including thrombopoietin (TPO), CXCL12, 
angiopoietin and stem cell factor (SCF) (Chute, Muramoto et al. 2006, 
Greenbaum, Hsu et al. 2013). Endothelial cells are also responsible for the 
migration/extravasation of leukocytes into and out of the BM. Indeed, the 
microvasculature represents a physical and functional barrier from the peripheral 
circulation.
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The hematopoietic parenchyma comprises HSCs and uncommitted hematopoietic 
progenitors, which colonize preferentially the endosteal and subendosteal niches. 
Conversely, committed progenitors and differentiated cells are distributed in the 
central and perisinusoidal niches, respectively (Bonomo, Monteiro et al. 2016). 
Quiescent HSCs are in close association with endosteal osteoblasts, but recent 
studies have suggest than only a small subpopulation of HSCs reside in this 
endosteal niche, whereas many HSCs are associated with the sinusoidal 
endothelium, which is referred to as the vascular niche (Kiel, Yilmaz et al. 2005, 
Kiel and Morrison 2006). As HSCs exit quiescence to enter a proliferative state, 
they migrate and colonize the subendosteal perivascular niche. Accordingly, 
maturation of cells in the BM follows a radial pattern, with progenitor cells residing 
close to the bone surface and differentiated cells in the inner part of BM 
parenchyma near central venous sinus (Figure 11).
BM regulates the functional maintenance of HSCs and immune cells through the 
presence of both hematopoietic and vascular niches, which are 
microenvironmental domains regulating proliferation, differentiation and 
quiescence. The regulation occurs either by direct cell-to-cell contact or through 
the secretion of growth factors, cytokines and components of the ECM (Mercier, 
Ragu et al. 2012).
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Figure 11 -  Schematic representation of BM microenvironment under homeostatic 
conditions
HSC area, which harbors hematopoietic stem cells and uncommitted progenitors, comprises both 
endosteal and subendosteal niches. Committed progenitors and differentiated cells are distributed 
in the central and perisinusoidal niches, respectively. Quiescent hematopoietic stem cells are in 
close association with endosteal osteoblasts and bone-lining cells. As HSCs exit quiescence to 
proliferative states, they migrate and colonize the subendosteal perivascular niche, interacting with 
both endothelial cells and pericytes. Subendosteal sinusoid-derived pericytes serve as source for 
new osteoprogenitors, which will differentiate into osteoblasts during bone remodeling
Adapted from Journal o f Cellular Biochemistry, 2014, Cordeiro-Spinetti et al.
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Spangrude and colleagues were the first to demonstrate that HSCs were the only 
cells, in mouse BM, capable of fully reconstitute the entire hematopoietic system 
when transplanted into lethally irradiated mice (Spangrude, Heimfeld et al. 1988). 
After this study, mouse HSCs have been extensively purified and identified using 
additional cell-surface markers (Challen, Boles et al. 2009). HSCs include three 
multipotent populations: Long-Term (LT)-HSCs (c-Kit+Lin-Sca-1+CD34'Flk2'), 
Short-Term (ST)-HSCs (c-Kit+Lin-Sca-1+CD34+Flk2'), and Multi Potent Progenitors 
(MPPs, c-Kit+Lin-Sca-1 +CD34+Flk2+).
LT-HSCs have self-renewal capability being able to maintain the stem cell pool or, 
alternatively, to differentiate into ST-HSCs or lineage-restricted progenitors that 
undergo extensive proliferation and differentiation to produce terminally 
differentiated hematopoietic cells. Immunophenotyping by flow cytometry (FC), 
using different cell surface markers, indicated that hematopoietic development has 
a hierarchical structure in which multi-potency is progressively restricted as cell 
specialization increases (Figure 12) (Seita and Weissman 2010).
HSCs initially give rise to the MPPs that no longer possess self-renewal ability, 
maintaining full-lineage differentiation potential, even if they are still 
heterogeneous. Further downstream, MPPs advance to oligo-potent progenitors: 
the common lymphoid progenitor (CLP, c-Kit+Lin'Sca-1+) and the common myeloid 
progenitor (CMP, CD34+CD16/32') (Kondo, Weissman et al. 1997, Akashi, Traver 
et al. 2000).
CLP gives rise to T and B lymphocytes, while CMP to megakaryocyte/erythroid 
progenitor (MEP, CD34'CD16/32) and to granulocyte/macrophage progenitor 
(GMP, CD34+CD16/32+) (Nakorn, Miyamoto et al. 2003, Pronk, Rossi et al. 2007).
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T and B lymphocytes, responsible for adaptive immunity, are distinguished by their 
site of differentiation. Mature T and B cells circulate between the blood and the 
peripheral lymphoid tissues and, after antigen recognition, B cells differentiate into 
antibody-secreting plasma cells, whereas T cells differentiate into effector T cells 
with a variety of functions. A third lineage of lymphoid-like cells, the natural killer 
(NK) cells, derive from the same progenitor but lack the antigen-specificity that is a 
hallmark of adaptive immune response.
Innate immune response is performed by leukocytes that derived from GMP such 
neutrophils, basophils and eosinophils (collectively known as granulocytes), 
macrophages and dendritic cells (DCs), whereas MEP gives rise to 
megakaryocites and mature erythrocytes.
Although BM, together with thymus, is a primary lymphoid organ and lacks 
organized T- and B-cell areas, the structural and functional features of the BM 
resemble a secondary lymphoid organ since it contains follicle-like structures 
similar to lymph nodes and spleen (Di Rosa and Pabst 2005). Indeed, in addition 
to its role as a primary lymphoid organ through the support of lymphoid 
development, BM can act as a host for various mature lymphoid cells. In fact, it is 
suggested that HSCs niche serves as “hub” for optimal T cell maintenance 
(Sabbagh, Snell et al. 2007).
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Figure 12 -  The hierarchy of hematopoietic cells
LT-HSC, long-term repopulating HSC; ST-HSC, short term repopulating HSC; MPP, multipotent 
progenitor; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; MEP, 
megakaryocyte/erythroid progenitor; GMP, granulocyte-macrophage progenitor. The encircled 
pluripotent population LT-HSC, ST-HSC and MPP are lin', Sca-1+, c-kit+.
From Larsson J. Oncogene 2005
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1.3.1 Bone marrow-derived immune cells
- T cells
Mouse BM contains 1 %-5% CD3+ T cells (about 1.5% of CD4+ and 2%-2.5% of 
CD8+ T cells) (Price and Cerny 1999). Among CD4+ cells approximately one-third 
are CD4+CD25+ regulatory T (Treg) cells (Zou, Barnett et al. 2004). Two-thirds of 
BM T cells express surface markers indicative of antigen experience, displaying a 
memory phenotype, such as high levels of CD44 (mouse-restricted marker) and 
CD122 (Mazo, Honczarenko et al. 2005). Treg cells can be mobilized from the BM 
by stimulation with granulocyte colony-stimulating factor (G-CSF) acting on 
CXCR4/CXCL12 signalling pathways (Zou, Barnett et al. 2004).
In addition, BM is the preferred site for proliferation of memory CD8+ T cells, which 
are able to mount an effective secondary response (Becker, Coley et al. 2005). 
Memory CD8+ T cells proliferate more extensively in the BM than they do in either 
secondary lymphoid or extra-lymphoid organs (Parretta, Cassese et al. 2005).
- B cells
As mentioned above, B cells develop and mature in BM before they egress into 
the peripheral blood. B cell development occurs preferentially in specific cellular 
niches associated with CXCL12- and IL-7- expressing cells and the transition from 
pre-pro-B cells to pro-B cells requires these signals. Recirculating memory B 
lymphocytes and active plasma cells secrete considerable levels of IL-6 and TGF- 
p, contributing to a myelopoietic balance (Tokoyoda, Egawa et al. 2004). CD4+ T 
cells, expressing CXCR4, provide substantial assistance to differentiating B 
lymphocytes and produce cytokines that regulate myelopoiesis (Tokoyoda, 
Zehentmeier et al. 2009).
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- NK cells (natural killer)
In normal adult mice, NK cells are found in thymus, bone marrow, liver and spleen 
and peripheral NK cells are rapidly deleted upon activation and replaced by NK 
cells that have been generated by de novo proliferation in the BM.
- Granulocytes
Collectively, basophils, eosinophils, and neutrophils are termed either 
granulocytes, because of the cytoplasmic granules that confer them a distinctive 
appearance in blood smears, or polymorphonuclear leukocytes, because of their 
irregularly shaped nuclei.
Eosinophils and basophils are recruited to sites of allergic inflammation and 
appear to be involved in the defense to parasites.
The protection from exogenous antigens and toxins is also exploited by mast cells 
that, arising from c-kit-expressing precursors in the BM, complete their maturation 
in tissues highly exposed to external environment.
Neutrophils are central effectors of innate immune responses because they are 
rapidly mobilized from the BM in case of infection and stress. The maintenance of 
neutrophils in the BM depends on CXCR4/CXCL12 signaling pathways (Eash, 
Means et al. 2009). Accordingly, the administration of G-CSF, which is reported to 
reduce the expression of CXCR4, mobilizes neutrophils from BM to peripheral 
circulation (Christopher, Liu et al. 2009).
- Dendritic cells (DC)
DCs play key role in both innate and adaptive immune responses. BM DCs are 
able to trigger central memory T cells-mediated responses and are essential for 
innate immunity to intracellular infection. Antigen presentation by BM DCs can
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induce also the expansion of Treg cells and activate their ability to suppress 
cytokine secretion by effector T cells (Banchereau, Briere et al. 2000, 
Guermonprez, Valladeau et al. 2002).
- Myeloid-derived cells
Myeloid-derived cells are a heterogeneous population of cells consisting of 
myeloid progenitors, immature myeloid cells and macrophages. Immature myeloid 
cells are generated in the BM and differentiate into mature myeloid cells under 
physiological condition. Nevertheless, immature myeloid cells expanded and 
activated in tumour microenvironment, can acquire immune suppressive function. 
These myeloid-derived suppressor cells (MDSCs) exploit their immunosuppressive 
activity by producing immune suppressive factors such as arginase I (ARG1) or 
inducible nitric oxidase synthase (iNOS) or TGF-|3 (Gabrilovich and Nagaraj 
2009). The nature and effector functions of MDSCs are described in details in 
chapter 1.3.3.
- Erythroid cells
In humans, erythropoiesis is confined to the BM, but in mice it also occurs in the 
spleen. The erythroid lineage derives from MEP, which can give rise to 
megakaryocyte and erythrocytes. The erythroid progenitor cells develop in two 
phases: erythroid burst-forming units (BFU-E) followed by the differentiation 
towards erythroid colony-forming unit-erythroid (CFU-e). This differentiation occurs 
upon stimulation with erythropoietin (EPO), which represents a critical factor for 
their maturation.
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1.3.2 Extramedullary haematopoiesis
Haematopoiesis that occurs in organs other than BM, in response to pathological 
processes such as tumour growth, is termed extramedullary haematopoiesis (EH). 
There are two main types of EH, active and passive: the first occurs during both 
fetal development and immune response following an infection; the latter occurs 
because of failed BM haematopoiesis, in order to in part vicariate its function. Both 
phenomena produce antigen-presenting cells, granulocytes, NK cells, red blood 
cells and platelets.
EH refers to a broad range of hematopoietic activities form the early stages of 
lineage commitment. In fact, many BM-derived cells require further maturation in 
peripheral tissue in order to become functional immune cells. For instance, 
monocytes complete their maturation in peripheral tissue in order to become 
macrophages or DCs and B cells must be activated in the periphery to become 
memory and plasma cells, respectively.
In mice, BM haematopoiesis is delayed and becomes functionally active after birth. 
In the fetus, the yolk sac and the fetal liver provide the need for hematopoietic cells 
(Lux, Yoshimoto et al. 2008). After birth, the BM becomes the predominant site of 
haematopoiesis, together with an increasing number of progenitors colonizing the 
spleen, which remains a hematopoietic organ during all lifetime. In addition, the 
fetal liver acts as a site of haematopoiesis after birth, even if at low level. Together, 
liver and spleen are the main sites of EH after the activation of immune responses 
in the periphery (Figure 13).
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Major forms of extramedullary haematopoiesis. Extramedullary haematopoiesis occurs early in fetal 
development and also plays important roles in adult life. Haematopoiesis occurs in the fetal liver 
and spleen. Hematopoietic stem and progenitor cells in the fetal liver migrate to the bone marrow 
and the marrow becomes the major hematopoietic site after birth. The hematopoietic stem and 
progenitor cells in the bone marrow emigrate to the periphery such as the liver and spleen. Upon 
infection and resultant immune responses, various hematopoietic factors including TLR ligands and 
cytokines promote extramedullary haematopoiesis in the liver and spleen. A major role of this 
extramedullary haematopoiesis is to produce functionally mature antigen-presenting cells and 
phagocytes. Excessive and prolonged extramedullary haematopoiesis in the periphery occurs in 
the presence of autoimmune diseases and chronic infection. In these situations, extramedullary 
haematopoiesis is harmful for the host. When malignant disease such as primary myelofibrosis 
occurs, the marrow becomes unsuitable to support haematopoiesis and extramedullary 
haematopoiesis is greatly increased
From Chang H Kim. J Blood Med. 2010
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In particular, in mice, the spleen has predominantly lympho-erythropoietic function 
and its parenchyma contains a red pulp with eryhtropoietic activity and a lymphoid 
tissue called white pulp colonized by T and B cells. The spleen has three main 
function: i) it is able to elicit specific T or B lymphocytes-mediated immune 
reaction; ii) it serves as a reservoir of erythrocytes in mice; iii) it filters the blood 
removing old cells or infectious agents thanks to the presence of resident 
macrophages (Cesta 2006).
Microbial components such as Toll-like receptor (TLR) ligands (i.e. LPS) can 
directly activate haematopoiesis, increasing myeloid cell number in BM and spleen 
after LPS injection in vivo. Accordingly, infection may significant affect 
haematopoiesis both in BM and in peripheral organs, rendering TLR ligands 
effective regulators of EH (Nagai, Garrett et al. 2006).
The increase in myelopoiesis induced by EH during infection can lead to the 
production of MDSCs, similarly to what occurs in cancer settings.
While programmed EH is required to supplement hematopoietic activity in the BM, 
an excessive and disease-associated EH can occur and mediate chronic 
inflammation.
1.3.3 Myeloid-derived suppressor cells
Abnormal function and differentiation of myeloid cells, which result in a 
bidirectional molecular crosstalk between tumour and myeloid progenitor cells, is a 
hallmark of cancer. The accumulation of MDSCs, harbouring immunosuppressive 
function, is common in tumours, where they support progression through different
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mechanisms such as promoting tumour cell survival, angiogenesis, invasion and 
metastasis formation (Condamine, Ramachandran et al. 2015).
Considering the phenotypic heterogeneity of this population the nomenclature of 
MDSCs remained debated until 2007, when MDSCs became the term for this 
cellular phenotype and function (Gabrilovich, Bronte et al. 2007). MDSCs are 
broadly defined as myeloid cells and represent a distinct population from terminally 
differentiated mature myeloid cells. Mouse MDSCs have been identified as 
CD11b+Gr1+ cells and, since Gr-1 is a combination of Ly6C and Ly6G markers, 
they can be accurately defined on the bases of these two molecules. 
CD11b+Ly6Gl0WLy6Chigh cells have a monocytic-like morphology, preferentially 
express iNOS, have an increased T cell suppressive activity and are identified as 
monocytic-MDSCs (Mo-MDSCs). In contrast, CD11b+Ly6GhighLy6Cl0W cells have a 
granulocyte-like morphology, express high levels of ARG1, and are identified as 
granulocytic-MDSCs (G-MDSCs) (Figure 14). These cells have a 
polymorphonuclear (PMN) morphology and, therefore, the term PMN-MDSC is 
used interchangeably with the term G-MDSC (Youn, Nagaraj et al. 2008). 
Mo-MDSCs and G-MDSCs present different mechanisms of immune suppression: 
Mo-MDSCs suppress both antigen-specific and non-specific T cell responses and 
have stronger suppressive activity than G-MDSCs; in contrast, G-MDSCs 
suppress only in an antigen-specific manner (Gabrilovich, Ostrand-Rosenberg et 
al. 2012). Several factors are implicated in MDSC-mediated immune suppression 
such as ARG1, iNOS, TGF-p, IL-10, COX2 and induction of Tregs (Huang, Pan et 
al. 2006, Youn, Nagaraj et al. 2008, Mao, Poschke et al. 2013).
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Figure 1 4 - Myeloid derived suppressor cells
Myeloid-derived suppressor cells (MDSCs) consist of two main subsets: monocytic MDSCs and 
granulocytic MDSCs. In most tumour models, Granulocytic subset of MDSCs has increased activity 
of signal transducer and activator of transcription 3 (STAT3) and NADPH, which results in high 
levels of reactive oxygen species (ROS) but low nitric oxide (NO) production. ROS induces the 
post-translational modification of T-cell receptors and may cause antigen-specific T-cell 
unresponsiveness. The monocytic MDSC subset has upregulated expression of STAT1 and 
inducible nitric oxide synthase (iNOS), and increased levels of NO but low ROS production. NO 
suppresses T-cell function through various different mechanisms that involve the inhibition of Janus 
kinase 3 and STAT5, the inhibition of MHC class II expression and the induction of T-cell 
apoptosis. Both subsets have increased levels of arginase 1, which causes T-cell suppression 
through depletion of L-arginine.
From Gabrilovich Nature Reviews Immunology 2009
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Cells with a MDSC-like phenotype have a key role in tumour development and 
progression even via mechanisms that are not necessarily related to their ability to 
suppress tumour-specific immune response. Generally, the ability of MDSCs to 
support tumour growth and metastases can be divided into: i) protection of tumour 
cells from immune-mediated killing; ii) remodelling of the tumour 
microenvironment; iii) establishment of a pre-metastatic niche and, iv) interaction 
with tumour cells to induce proliferation and facilitate epithelial-to-mesenchymal 
transition (EMT).
In cancer, the accumulation of MDSCs requires two sets of signals. The first set 
supports their expansion and it is mediated mainly by GM-CSF, M-CSF, G-CSF 
and other growth factors produced by tumour cells and tumour stroma. Tumours 
that stimulate MDSC proliferation have been shown to secrete VEGF-A 
(Gabrilovich, Ishida et al. 1998, Melani, Chiodoni et al. 2003), GM-CSF (Bronte, 
Chappell et al. 1999), SCF (Pan, Wang et al. 2008), FMS-like tyrosine kinase 3 
ligand (FLT3L) (Solheim, Reber et al. 2007), G-CSF (Waight, Hu et al. 2011) and 
M-CSF (Sawanobori, Ueha et al. 2008). Indeed, using transplantable tumour 
models, it has been shown that tumour-derived GM-CSF induces MDSC 
expansion and it is sufficient to generate immunosuppressive MDSCs in vitro 
(Bayne, Beatty et al. 2012).
Consistent with these studies, antibody neutralization or molecular inhibition of 
such secreted factors has been shown to reduce MDSC accumulation in the 
tumour microenvironment and to delay tumour development.
Although the expression of these factors is sufficient to expand MDSC, a second 
set of signals is required in order to confer them a suppressive phenotype. Several
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pro-inflammatory cytokines such IL-6, TNF-cx, IFN-y and IL-1 (3 are responsible for 
the induction of immunosuppressive capabilities (Gabrilovich, Ostrand-Rosenberg 
et al. 2012). Also, members of signal transducer and activator of transcription 
(STAT), such as STAT3, can regulate MDSC accumulation and suppressive 
functions acting on ARG1 production via C/EBP|3 and IFN regulatory factor-8 
(IRF8) (Waight, Netherby et al. 2013). Moreover, hypoxia-inducible factor 1 a 
(HIF1-a) promotes the suppressive activity of MDSCs via up-regulation of iNOS 
and ARG1 (Corzo, Condamine et al. 2010).
Recently, endoplasmic reticulum stress response, which protects cells form stress 
signals, has been shown to have a role in the immune suppression mediated by 
MDSCs (Mahadevan, Rodvold et al. 2011). For instance, MDSCs from tumour- 
bearing mice and cancer patients showed increased expression of DNA-damage- 
inducible transcript 3 (CHOP) and tumour MDSCs lacking Chop have decreased 
immune-regulatory functions and showed the ability to prime T cell function and 
induce antitumour responses (Thevenot, Sierra et al. 2014).
High mobility group box 1 (HMGB1) and peroxisome proliferator activated receptor 
gamma (PPARy) have also been shown to contribute to immunosuppressive 
activity of MDSCs and have been recently added to the list of inflammatory 
mediators that control MDSC function (Wu, Yan et al. 2012, Parker, Sinha et al. 
2014).
In several studies numbers of MDSCs correlate with poor prognosis, tumour 
vasculogenesis and tumour evasion of host immunity; a direct relationship 
between tumour burden and MDSC frequency has been demonstrated in several 
mouse tumour models (Donkor, Lahue et al. 2009, Younos, Dafferner et al. 2012)
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and in clinical studies (Hickey 1991, Porembka, Mitchem et al. 2012, Wang, 
Chang et al. 2013).
Confirmation of these observations using transplantable tumours has been 
demonstrated in a FVB-NeuN model of mammary carcinogenesis (Abe, Dafferner 
et al. 2010), where a direct association between the development of metastatic 
mammary tumours and expansion of MDSCs subset has been shown.
G-MDSC subset is the predominant MDSC population in tumour-bearing mice, 
whereas Mo-MDSC frequency is increased in a limited number of tumour models. 
Studies using 4T1 tumour-bearing mice revealed a high frequency of G-MDSCs 
with a higher proliferation rate in in BM and spleen (Youn, Nagaraj et al. 2008). 
Moreover, tumour-induced T cell-suppressive Ly6G+ myeloid cells are generated 
from an expanded stem and early progenitor compartment along with GMPs in BM 
of tumour-bearing mice (Casbon, Reynaud et al. 2015). In the same study the 
authors demonstrate that tumour production of G-CSF induces chronic activation 
of myeloid differentiation in the BM, which ultimately results in inefficient 
erythropoiesis, anemia, and enlarged spleens to meet the demands of neutrophil 
and red blood cells production during tumour progression.
MDSCs possess the ability to support tumour growth also through the remodeling 
of the tumour microenvironment producing VEGF and matrix-metalloproteinase-9 
(MMP9), which are essential mediators of neoangiogenesis and tissue invasion, 
respectively (Tartour, Pere et al. 2011).
Tumour progression in BALB-NeuT mice is paralleled by the expansion of MDSCs 
and by the increase of VEGF and MMP-9 in the serum of tumour-bearing mice 
(Melani, Sangaletti et al. 2007). Indeed, tumour-derived VEGF is a key factor in the
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expansion and function of MDSCs together with MMP9, which plays a central role 
in regulating the mobilization of HSCs from the BM (Heissig, Hattori et al. 2002). 
Mobilization from the BM is the first step of myeloid progenitor trafficking to 
inflammatory or tumour sites and it includes processes of alteration in cell-to-cell 
contact between myeloid progenitor and stromal cells.
In humans and mice, the treatment with selective antagonist of CXCR4 or CXCR4- 
blocking antibodies, results in a rapid mobilization of neutrophils, myeloid 
progenitors and MDSCs into the blood (Levesque, Hendy et al. 2003, Sawanobori, 
Ueha et al. 2008). This suggests that the disruption of CXCR4 signaling can 
contribute to G-CSF-induced mobilization and myelopoiesis. G-CSF administration 
also induces protease secretion in the BM microenvironment, thus contributing to 
mobilization (Levesque, Hendy et al. 2002). Accumulating evidences suggest that 
CXCL12 has a key role in controlling myeloid cell mobilization and homeostasis; in 
fact, CXCL12 or CXCR4 deficient mice die prenatally with neutrophilia and fail to 
establish BM haematopoiesis (Nagasawa, Hirota et al. 1996).
1.4 The role of Atf3 in cancer
As mentioned above, several lines of evidence have shaped the concept that 
tumourigenesis is a process regulated by a complex network of interactions 
between tumour cells, stromal cells, immune cells and the ECM, establishing a 
vicious cycle that fuels tumourigenesis.
In this scenario, considering the stress response as an early event in the 
neoplastic transformation, molecules involved in this process may contribute to 
cancer development and/or progression.
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Activating transcription factor 3 (Atf3) is a immune transcription factor encoding for 
a member of the ATF/cyclic adenosine monophosphate response element-binding 
family of transcription factors, which share the basic region/leucine zipper DNA- 
binding motif and bind to the CREB/ATF and AP-1 consensus sequence (Hai and 
Hartman 2001).
Atf3 acts as a stress response protein, responding in normal cells to a plethora of 
insults such as endoplasmic reticulum stress, DNA damage, tissue injury and 
metabolic stress, through either induction or repression of different targets (Hai, 
Wolfgang et al. 1999).
For instance, when Atf3 is induced by TLR signaling, it inhibits the transcription of 
genes encoding pro-inflammatory mediators (Gilchrist, Thorsson et al. 2006). 
Transient TLR-driven signals induce NF-kB mediated-Atf3 transcription, which 
attenuates the expression of other NF-kB targets. Nevertheless, when TLR 
stimulation becomes persistent, the transcription of the NF-kB enhancer, C/EBP-5, 
augments NF-kB signaling and overcomes Atf3-mediated inhibition (Litvak, 
Ramsey et al. 2009).
It has been shown that Atf3 is necessary to restrain the activation of the immune 
response in models of sepsis and in LPS-induced responses (Elizur, Adair-Kirk et 
al. 2007). Based on these findings Atf3 may be viewed as a “hub” of the cellular 
adaptive response network that helps cells to adapt to disturbance of homeostasis 
(Hai, Wolford et al. 2010).
Because of its activation in case of homeostasis alteration, the function of Atf3 has 
also been studied in cancer development and progression. Studies in cancer 
biology, highlighted Atf3 as a dichotomous protein, which may act as a tumour
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suppressor, protecting normal and cancer cells from further transformation or as 
an oncogene, which is able to facilitate tumour progression, depending on the 
tumour type and its genetic portrait (Yin, Dewille et al. 2008, Thompson, Xu et al. 
2009) (Figure 15).
The role of Atf3 as tumour suppressor is supported by pieces of evidence showing 
that the down-regulation of Atf3 in colon cancer promotes tumour growth and 
metastasis (Hackl, Lang et al. 2010) and its over-expression reduced the invasive 
potential of ovarian, bladder and lung cancer cells (Syed, Mukherjee et al. 2005, 
Jan, Tsai et al. 2012, Yuan, Yu et al. 2013).
However, its constitutive expression in a large portion of cancers suggest that, in 
many cases, Atf3 may exert oncogenic activities, directly on tumour cells or 
through its activity on the surrounding stroma. In fact, human BC samples showed 
a stromal cytoplasmatic expression pattern of Atf3 and Atf3 expression levels were 
significantly elevated in cancer-associated stroma from BC patients in comparison 
with normal stroma. In this setting, there was a correlation between CXCL12 and 
Atf3 as staining for CXCL12 was evident in ECM surrounding the Atf3-expressing 
cells (Buganim, Madar et al. 2011). Other studies have shown also that Atf3 might 
affect other members of the tumour stroma such as endothelial cells, smooth 
muscle cells and macrophages. In fact, Atf3 was shown to protect endothelial cells 
from TNFa-induced cell death (Kawauchi, Zhang et al. 2002) and the induction of 
Atf3 in these cells endowed them with the ability to form tubule structures 
(Okamoto, Iwamoto et al. 2006). In addition, Atf3 increases the survival and 
enhances the migration of vascular smooth muscle cells (Lv, Meng et al. 2011). 
These findings indicate that Atf3 might be involved in cancer progression through
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the ability to promote the survival and formation of blood vessels in the vicinity of 
the tumour.
An oncogenic role for Atf3 has been shown in MCF10CA1 breast cancer epithelial 
cells since it is able to protect these cells from stress-induced cell cycle arrest, 
enhance their cell motility and EMT, thus increasing their tumour initiating features 
(Yin, Dewille et al. 2008, Yin, Wolford et al. 2010). Atf3 is found to be 
overexpressed in human breast tumours and, although the expression of Atf3 in 
breast cancer epithelial cells does not have clinical relevance, its expression in the 
stroma, specifically in mononuclear cells, correlates with worse outcome and with 
a higher proliferation rate assessed by Ki67 expression in the tumour. These 
findings highlighted an important role of Atf3 in mediating myeloid lineage 
responses in the TME and in favouring metastasis formation (Wolford, 
McConoughey et al. 2013). Accordingly, the macrophage/myeloid population is a 
key cell type in which Atf3 plays a functionally important role to facilitate 
metastasis. MMP9 is a direct target gene of ATF3 in macrophages and it is 
important for macrophages to enhance cancer cell invasiveness and 
transendothelial migration in vitro (Figure 16).
In PyMT mice, Atf3 expression in TAMs is induced by signals present in the TME 
and consistent with this observation, Atf3 is induced in BM-derived macrophages 
by IL-4, TGF-|3 hypoxia and co-culture with cancer cells (Wolford, McConoughey et 
al. 2013).
Although Atf3 function has been more extensively studied in macrophages and 
myeloid cells, it is able to mediate stress signals also in other cell types such as T 
cells, B cells, fibroblasts, adipocytes and endothelial cells.
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Figure 15 -  Dichotomous role of Atf3
The role of ATF3 in host defense via the regulation of immune responses and cancer progression. 
In inactive immune cells, including macrophages, NK cells and CD4+, ATF3 expression is 
maintained at low levels. Following activation of these cells by various signaling pathways, ATF3 is 
rapidly induced where it then binds its target promoters to regulate transcription. NF-kB and AP-1 
are transcription factors, well known for their ability to promote transcription of inflammatory 
cytokines and chemokines. ATF3 appears to directly antagonise NF-kB and AP-1 driven 
promoters, resulting in decreased expression of distinct subsets of cytokines and chemokines. 
Overall, ATF3 is therefore able to limit the intensity of the inflammatory response to infection and 
allergy, and ultimately prevent pathological conditions associated with uncontrolled output of 
inflammatory mediators. Controversially, ATF3 has also been suggested to plays roles as both a 
tumour suppressor and oncogene. Although the mechanisms that regulate ATF3 induction in 
cancer cells are largely unclear, it is possible that ATF3 could prevent tumour growth by repressing 
transcription of cell cycle genes (such as cyclin D1 and Id1) and cell survival genes (such as IRS2). 
Conversely, induction of metastatic mediators FN-1, TWIST-1 and Slug, or suppression of 
GADD153, a known pro-apoptotic gene, may implicate ATF3 as an oncogene.
From Thompson M. J  Mol Med 2009
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Model by which ATF3, a hub of the cellular adaptive response network, links various signals in the 
tumour microenvironment to alterations in macrophage transcriptional programs and bioactivities.
From Wo If rod CC J C I2013
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Taking in consideration all the aspects introduced so far, breast cancer features 
not only depend on the tissue where the transformation occurs but also on signals 
deriving from other organs. Since the tumour microenvironment is mainly 
composed of BM-derived immune cells, the importance of the BM in tumour 
development and progression is likely crucial. The immune system plays a key 
role in determining the fate of tumour cells, therefore the assessment of tumour- 
induced modification of haematopoiesis is relevant in understanding which 
variations in the BM are induced by tumour growth and which cell populations are 
involved in this process. The cross-communication between tumour cells and the 
surrounding environment is provided by several soluble factors, some of them 
circulating through the peripheral blood, being able to reach the BM parenchyma 
and tune, through local rearrangement, the quality of its response. Among the 
plethora of signals that are present in the circulation an important role is played by 
microRNAs, in light of their ability to modify the transcriptional program of several 
cells, also within the BM. As consequence, microRNAs may modulate the quality 
and the quantity of specific cell subsets that, once released from the BM, could 
reach the transforming tissue determining the fate of nascent tumours. The project 
described hereafter, focusing the attention on all the aspects that can modify the 
tumour development and assessing which signals may represent biomarkers of an 
incipient malignancy would offer a complete and precise picture of the 
modifications induced by the presence of a nascent tumour. Among them, it will be 
possible to identify those deserving more attention for an early diagnosis of 
neoplasia. Thanks to the recent advantages in microRNA and gene expression 
profile technology, the assessment of the transcriptional program of the BM and
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the profile of microRNA both in BM and in the circulation, together with a deep 
immunephenotyping analysis, results in a combined approach in which all the 
modifications can be related to a specific stage of the disease.
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2 Materials and Methods
2.1 Mice
Animals were maintained under pathogen free condition in filter-top cages at the 
animal facility of Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan 
(authorization number: 240936/2005). All procedures involving animals were 
approved and performed in accordance with institutional guidelines and national 
law (D.lgs26/14), as well as the Declaration of Helsinki. BALB-NeuT female mice 
express the transforming rat oncogene c-erB2 (Her-2/neu) under the mouse 
mammary tumour virus (MMTV) promoter and spontaneously develop mammary 
carcinomas within a well-defined tumour progression time frame (Lucchini, Sacco 
et al. 1992, Boggio, Nicoletti et al. 1998). Female BALB/c mice were crossed with 
male NeuT mice and progeny was screened at 3 weeks of age for the presence of 
NeuT transgene by polymerase chain reaction (PCR). Her-2/neu-positive female 
were monitored weekly for mammary tumour development and progression, 
whereas non-transgenic littermates (wild type mice) served as age-matched 
controls.
PyMT mice (C57BL/6 genetic background), express the oncogene Polyoma Middle 
T antigen under the MMTV promoter and develop mammary tumours at around 
15-18 weeks of age (Lin, Jones et al. 2003). PyMT transgenic female were 
crossed with male C57BL/6 wild type and progeny was screened at 3 weeks of 
age for the presence of the transgene by PCR. Female carrying the oncogene
70
________________________ Materials and methods______________________
were monitored weekly for mammary tumour development and progression, 
whereas non-transgenic littermates were used as age-matched controls 
Similarly to BALB-NeuT, huHer2D16 mice (FVB genetic background) carry, under 
MMTV promoter, the human HER2 splice variant lacking exon-16 (Marchini, 
Gabrielli et al. 2011). The transgenic females developed multifocal mammary 
tumours with a rapid onset and an average latency of 15 weeks (Castagnoli, lezzi 
et al. 2014). huHer2D16 mutated female, gently provided by Dr. Serenella Pupa, 
were crossed with male FVB wild type and progeny was screened at 3 weeks of 
age for the presence of the mutated allele by PCR. Female carrying the HER2 
splice variant were monitored weekly for mammary tumour development and 
progression, wild type littermates were used as age-matched controls.
Separate groups of mice of each strain were sacrificed at:
• 6 or 9 and 12 weeks of age, time points that reflect early stages of tumour 
onset, in which tumour mass is not palpable yet, but tissue begin the 
transforming process;
• 24 weeks of age as representative of late time point when overt tumours are 
evident.
2.2 Collection of tissues, cells and surgery
Femurs and tibiae were collected bilaterally. Bone marrow (BM) cells were 
obtained by flushing femurs and tibiae with PBS 1X supplemented with 2% heat- 
inactivated fetal calf serum (FCS), with the use of a 22-gauge needle attached to a 
1 -mL syringe. 500 ul of blood was collected by intracardiac puncture with 20 ul of 
EDTA 0.5 M pH 8.0. 100-150 ul of blood was collected separately for flow
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cytometry (FC) analysis and the remaining volume was processed for plasma 
separation within 2 hours. After surgical removal of the spleen, the organ was cut 
in two pieces: one piece was used as source of fresh cells; the other piece was 
used for histological analysis.
Fresh cells were obtained by mechanical disgregation of the organ in PBS 1X 
supplemented with 2% heat-inactivated FCS. Tissues for histological analysis 
were fixed in 10% neutral buffered formalin for almost 24 hours, washed in H20  
and stored in 80% EtOH before embedding in paraffin.
In addition to spleen, also mammary glands, contralateral femurs and tibias were 
collected for histological analysis.
In splenectomy experiments, spleens of 4 weeks NeuT and wt mice were 
surgically removed under aseptic conditions. Briefly, under anaesthesia with an 
intraperitoneal injection of ketamine (100 mg/Kg) and xylazine (5 mg/kg), a left 
flank incision was made to expose the spleen. The splenic blood vessels were 
cauterized using an electrocautery and the spleen removed by transecting the 
vessels just distal to the cauterized section. The peritoneum and the skin incisions 
were closed with wound clips, after checking for any haemorrhage in the 
abdominal cavity. Sham-operation was performed according to the splenectomy 
procedure but without removing the spleen.
2.3 Flow cytometry
Single-cell suspension preparations were treated with ACK lysis buffer 
(ammonium chloride potassium) on ice for 5 minutes to remove red blood cells. In 
order to avoid non-specific ligation of antibody to cells, each sample of
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differentiated cells, BM, spleen and blood cells was Fc-blocked by CD16/32 
antibody (eBioscience) before adding the specific antibodies. The following 
antibodies were used: Allophycocyanin-eFluor® 780 conjugated anti-mouse B220; 
PE-conjugated anti-mouse CD11b; FITC-conjugated anti-mouse F480, 
allophycocyanin conjugated anti-mouse Ly6C, PerCP-Cy5.5 conjugated anti­
mouse Ly6G (Gr-1) and PE-Cy7 conjugated anti-mouse CD3 (all from 
eBioscience). For progenitors the following antibodies were used: PE-conjugated 
anti-mouse CD11b, CD11c, B220, Ly6G (Gr-1), Ter119, CD3, Pe-Cy7 conjugated 
anti-mouse CD117 (c-kit), FITC-conjugated anti-mouse CD34 and PerCP-Cy5.5 
conjugated anti-mouse CD16/32 (all from eBioscience). For the evaluation of 
erythroid progenitors fresh blood cells were stained with FITC-conjugated anti­
mouse CD71, PE-conjugated anti-mouse Ter119, PerCP-Cy5.5 conjugated anti­
mouse CD11b, Pe-Cy7 conjugated anti-mouse CD117 (c-kit) and allophycocyanin- 
eFIuor® 780 conjugated anti-mouse B220 (all from eBioscience). Antibodies were 
used at a final concentration of 5 pg/ml. Samples were acquired using a BD LSR II 
Fortessa instrument (Becton Dickinson) and analysed with FlowJo software 
(version 8.8.7, TreeStar). All samples were analysed in single; in each experiment 
at least 3 samples per group were analysed.
2.4 RNA extraction
Total RNA was extracted from BM cells using Trizol reagent (Life Technologies) 
following the manufacturer’s instruction. RNA was treated with DNAse (Qiagen, 
Santa Clara, USA) and quantified by spectrophotometry (ND-2000c; NanoDrop 
Products, Wilmington, DE). Total RNA was extracted from plasma samples using
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the commercial column-based system Qiagen miRNeasy® Mini Kit (Qiagen, 
Valencia, CA, USA), slightly modified by Exiqon (Vedbaek, Denmark) as described 
before (Callari, Tiberio et al. 2013). RNA integrity for microarray experiments was 
verified using the RNA 6000 Nano Kit (Agilent Technologies, Palo Alto, USA); all 
samples had an RNA integrity number (RIN) > 7, indicating good quality.
2.5 Gene expression and microRNA profiles
For gene expression profile (GEP), RNA was reverse transcribed, labeled with 
biotin and amplified overnight using the lllumina TotalPrep RNA Amplification Kit 
(Life Technologies). Biotinylated complementary RNA was hybridized to 
mouseWG-6 v2.0 Expression BeadChips (lllumina, San Diego, USA).
To assess the expression levels of microRNAs lllumina mouseWG-6 v2.0 
microarrays designed on miRBase 19.0 from Agilent Technologies were used as 
described before (Callari, Tiberio et al. 2013).
For GEP profiling, lllumina mouseWG-6 v2.0 Expression BeadChips microarrays 
were scanned with lllumina BeadArray Reader, and raw data obtained using 
lllumina BeadStudio v3.3.8 were processed using the lumi package (Du, Kibbe et 
al. 2008) from R/Bioconductor (Huber, Carey et al. 2015). Raw data were log2- 
transformed, normalised using robust spline normalisation and filtered; only the 
probes with a detection p-value <0.01 in at least one sample were further 
analysed. Multiple probes representing the same gene were collapsed, and the 
probe with the highest detection rate was selected. In the case of equal detection 
rates, the probe with the greatest variation, as indicated by the interquartile range, 
was selected. For microRNA profiling, mouse miRNA miRBase 18.0 microarrays
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from Agilent were scanned with an Agilent SureScan scanner, and raw data were 
collected using Agilent’s Feature Extraction software v10.7. Raw data were pre- 
processed using an optimized version of the RMA algorithm implemented in the 
AgiMicroRna package (Lopez-Romero 2011). Data for bone marrow microRNA 
profiles were log2-transformed and normalised with quantile normalisation. For 
circulating microRNAs data were log2-transformed only, as standard normalisation 
strategies are not suitable for circulating microRNA data. microRNAs that were 
detected in at least 50% of samples, as indicated by the glsGeneDetected 
parameter given by the Feature Extraction software, were kept for further 
analyses.
To merge gene expression data from different set of samples we applied ComBat 
to correct for batch effects.
For unsupervised analysis we merged gene expression data from the discovery 
and validation set to increase the number of samples. ComBat (Johnson, Li et al.
2007) was applied to remove the batch effect. Hierarchical clustering was applied 
with average linkage and 1-Pearson’s correlation coefficient as distance metric.
2.6 Forced haemolysis
From an intracardiac puncture, using the same mouse, we collected 2 aliquots of 
plasma: one was maintained at 4° and the other one was centrifuged for 5 
seconds at maximum speed in order to force an experimental-induced haemolysis. 
Both samples were considered haemolysed with a value > 0.2 at 414 nm of 
absorbance measured with spectrophotometer (ND-2000c; NanoDrop Products, 
Wilmington, DE).
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2.7 Histology and immunohistochemistry
The BM and mammary glands were fixed with 10% neutral buffered formalin for 24 
hours, washed with abundant H20  and then paraffin embedded. Subsequently, 
four-micrometers-thick sections were cut and used for both morphological 
(haematoxylin & eosin, H&E) and immunohistochemistry (IHC) staining.
Before H&E and IHC staining tissue sections were deparaffinised and rehydrated. 
IHC was performed using a polymer detection method. (Novolink Polymer 
Detection Systems Novocastra Leica Biosystems Newcastle Ltd Product No: 
RE7280-K). The antigen unmasking technique was performed using Novocastra 
Epitope Retrieval Solutions pH 9 in PT Link Dako at 98°C for 30 minutes. 
Subsequently, the sections were brought to room temperature and washed in 
PBS. After neutralization of the endogenous peroxidase with 3% H20 2 and Fc 
blocking by a specific protein block the samples were incubated over night with the 
primary antibodies Mouse Monoclonal CXCL12/SDF-1 (Clone #79018; 1:50 pH 6; 
R&D Systems), Rabbit Monoclonal CXCR4 (Clone UMB2; 1:100 pH 6; Epitomics), 
Mouse Monoclonal Nestin (Clone rat-401; 1:100 pH 9; Millipore); Rabbit Polyclonal 
ATF3 Activating transcription factor 3 (1:200 pH 6; Sigma-Aldrich) at 4 C°. Staining 
was revealed by polymer detection kit (Novocastra) and AEC (3-Amino-9- 
Ethylcarbazole) substrate chromogen. The slides were counterstained with Harris 
hematoxylin (Novocastra). Negative control stainings were performed by using 
mouse and rabbit immune sera instead of the primary antibodies. All the sections 
were analysed under a Zeiss AXIO Scope.AI optical microscope (Zeiss 
Oberkochen Germany) and microphotographs were collected using a Zeiss 
Axiocam 503 Color.
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2.8 Real-Time PCR analysis
For quantitative Real-Time PCR, RNA (0.1 jjg) was reverse transcribed with the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystem) according to 
manufacturer’s instructions. Real-Time PCR (RT-PCR) reactions were performed 
on ABI Prism 7900 HT (Applied Biosystem) using the TaqMan® Fast Universal 
PCR MasterMix (Applied Biosystem) according to manufacturer’s instructions. 
Expression levels of each gene (Atf3, mmp9, II-6) were normalised through the 
comparison with mouse Gapdh expression. Following probes have been used: 
Atf3 (Mm.PT.58.41654515 by IDT) ; mmp9: (Mm00442991_m1 by ThermoFisher 
Scientific), il-6 (Mm.PT.58.10005566 by IDT) and Gapdh (Mm.PT.39a.1b by IDT) 
Results were obtained using the comparative Ct method (Schmittgen and Livak
2008).
2.9 Western Blot analysis
Cells were lysed in a buffer containing 50 mM Tris HCI (pH 7.4); 150 mM NaCI; 1%
Triton X-100; 0.1% SDS; 10 pg/ml Aprotinin (Sigma-Aldrich); 10 pg/ml Leupeptin
(Sigma-Aldrich); 1 mM PMSF (Sigma) for 20 min at 4°C. The lysates were then
centrifuged at 12,000 g for 10 min at 4°C and the supernatant collected. Lysates
were subjected to Pierce™ BCA Protein assay kit (ThermoFisher) for total protein
quantification before storing them at -80°C. After the determination of total proteins
in samples, 20 pg for each sample were loaded on 10% or 4-12% Bis-Tris Gels
(Novex, Invitrogen) and subjected to electrophoresis at constant 100 V in a X-Cell
SureLock (Invitrogen) electrophoresis cell according to the manufacturer’s
instructions and using a SDS running buffer (0.025 M tris-base pH 8.8; 0.192 M
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glycine; 0.1% SDS). Sodium Dodecyl Sulfate Poly-Acrylamide Gel Electrophoresis 
(SDS-PAGE) was performed as described in (Sambrook and Gething 1989) using 
a discontinuous buffer system (Laemmli 1970). This allows separation of proteins 
according to their relative molecular weight. The proteins were transferred from the 
gel to nitrocellulose blotting membranes (Amersham™ Protran™ 0.45 \xm NC) 
previously activated in 100% methanol and transfer at 100 V for 1 hour. After 
electroblotting, the membranes were stained with Ponceau S to verify equal 
loading and transfer. Membranes were blocked in 5% low fat milk or BSA in TBS-T 
1X for 1 hour then were incubated first with the primary antibody in TBS-T 5% milk 
or BSA for 1-12 hours depending on the antibody and after with a secondary 
antibody linked to the horse-radish peroxidase for 1 hour. The membranes were 
then washed and developed using enhanced chemiluminescence (ECL, 
Amersham). The following antibodies were used in these assays: anti-Atf3 1:200 
(Santa Cruz, C-19, #sc-188) and anti-|3-actin 1:2000 (Sigma, #A2006).
Membranes were exposed to autoradiography using high performance 
autoradiography film (Hyperfilm MP, Amersham Biosciences) and developed by an 
automatic developer (Curix 60, AGFA). For re-probing with different antibodies, 
membranes were incubated with a commercially available stripping buffer (Restore 
Western Blot Stripping Buffer, Pierce) for 45 minutes and stripping of the 
antibodies was checked by exposure of membranes to autoradiography as 
described above, before incubation with a different antibody.
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2.10 Cell cultures
Human embryonic kidney (293T cells), mouse leukaemic monocyte macrophage 
RAW 264.7 (RAW) and mouse macrophage MT2 cell lines were cultured in DMEM 
(Gibco®) supplemented with 10% FCS, penicillin (100 U/mL), streptomycin 
(100mg/mL), non essential amino acids (NEEA)(Lonza), sodium pyruvate (1 
pm)(Lonza) and N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) 
0.01 M (Lonza). Mouse monocyte macrophage J774 cell line was cultured in RPMI 
1640 (Lonza) supplemented as above described for DMEM.
2.11 Lentivirus production
Atf3-encoding lentiviral vector was constructed replacing the GFP sequence of 
pRRLsinCD68GFP.WprePGKNGFR, a myeloid specific lentiviral vector previously 
developed in our laboratory, with mouse mAtf3 coding sequence. A third- 
generation packaging system involving the transfection of four plasmids in the 
producer cells, namely two packaging plasmids (pMDLg/pRRE and pRSV-REV), 
an envelope plasmid (pMD2-VSV-G), and the lentiviral vector, was used. Lentiviral 
stocks were produced in 293T cells by Ca3P04 co-transfection of the four 
plasmids. Twenty-four hours after transfection, the virus containing supernatant 
was harvested, passed through a 0.22 pm filter and purified by ultracentrifugation 
as described previously (De Palma and Naldini 2002). The viral stocks were stored 
at -80°c and the viral titer was assessed by expression of hNGFR (PE-conjugated 
anti-human) by FC in 293T cells infected with different dilution of virus. The 
presence of the truncated human NGFR reporter sequence allows an optimal
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selection of cells after the infection. Infection of macrophage cell lines was 
performed at different multiplicity of infection (MOI), in presence of polybrene.
Lin" cells isolated from wt mice were prestimulated overnight in Stemspan SFEM 
(STEMCELL Technologies) supplemented with 100 ng/mL SCF, 100 ng/mL Flt3L, 
50 ng/mL TPO, 20 ng/mL IL3, and then lentiviral particles were added at a MOI 
100. After 24 hours, cells were washed, counted and used for subsequent 
experiment (CFU assay). Infection efficiency was assessed by FC analysis 
evaluating the expression of the hNGFR. Infected cells were positively selected 
with Anti-Phycoerythrin (PE) MicroBeads (Milteny) after the incubation with a- 
CD271 (hNGFR, cat.557196 BD Pharmigen) following mchanufacturer’s 
instruction. CFU assay was performed using Methocult (#3434 StemCell) following 
manufacturer’s instruction.
2.12 In silico analysis
Gene Set Enrichment Analysis was carried out using GSEA (Subramanian, 
Tamayo et al. 2005) in pre-ranked mode using the c2_all collection form MSigDB 
database. Gene sets with a false discovery rate < 0.05 were considered 
statistically significant. Functional analysis of differentially expressed genes was 
carried out through Gene Ontology (biological processes domain). To estimate the 
relative amount of immune cells in the BM we applied CIBERSORT (Newman, Liu 
et al. 2015) to GEP data.
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2.13 Statistical analysis
The analysis of data was performed using Prism software (GraphPad Software, 
Inc). Results are expressed as means ± SEM or SD. Statistical analysis was 
performed using a two-tailed Student’s t-test with confidence intervals of 95%. 
Data were considered significantly different at p<0.05 (*px0.05, **p<0.01, 
***p<0.005 by two-tailed Student’s t test). Differential expression analysis of 
microarray data was carried out using the limma package. P-values were 
corrected for multiple testing using the Benjamini-Hochberg false discovery rate 
(FDR) method. An FDR < 0.05 was considered statistically significant.
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3 Aim of the study
The identification of early modifications induced by an incipient process of 
transformation is crucial to identify and treat cancers when they are still confined in 
a tissue. Considering the important role played by the immune system in tumour 
progression, the BM could be considered an important sensor of such 
phenomena. The aim of this work was to identify the variation in the BM that 
occurs concomitantly to an ongoing neoplastic transformation in a distant site. The 
hypothesis that BM is an early sensor of incipient neoplasia has been investigated 
taking advantage of animal models spontaneously developing mammary tumours. 
The use of mouse models offers the possibility to study the process of 
carcinogenesis starting from very early phases, an analysis difficult to be 
performed in the human setting.
The identification and characterisation of early changes occurring in the BM during 
tumour progression could offer the opportunity to identify key signals involved in 
the crosstalk between a developing tumour and the immune system, which could 
serve as early biomarkers of carcinogenesis.
In addition, the precise identification of those BM-centered modifications that are 
functionally relevant for the progression of nascent neoplasia could allow the 
discovery of novel potential therapeutic targets.
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4 Results
4.1 Overt changes in bone marrow, spleen and peripheral blood 
populations are present in tumour-bearing mice and a trend 
of same modification characterizes mice with pre-cancerous 
lesions
It is well known that the immune system may play a crucial role during tumour 
development and progression mediating the process of immunesurveillance. In 
order to investigate whether and how an ongoing process of mammary 
carcinogenesis may impact on the hematopoietic compartment, BM, spleen and 
PBL of NeuT trangenic mice at different time points of tumour progression have 
been collected. A deep characterisation of their composition in terms of immune 
population has been performed at different stages of neoplastic progression taking 
advantage of different methodologies such as immunohistochemistry, FC and 
gene profiling. All the analyses have been carried out on specimens from the 
same mice in order to maximize the comparability of the results obtained by 
different methodologies.
Firstly, FC analyses have been performed to characterize the composition of 
differentiated and progenitors cells in BM and spleen, as well as differentiated cells 
circulating in the peripheral blood. A particular attention has been given to the 
myeloid compartment, since its role in tumour progression has already been 
shown in NeuT transgenic mice in which VEGF released by the tumour is the main
83
___________ __________________  Results_____________________________
factor that conditions haematopoiesis toward the expansion of CD11b7Gr1 + 
myeloid population (12750171).
The analysis has been firstly performed at late time points (24 weeks of age), 
when invasive carcinomas are fully developed. This served as positive reference 
for the subsequent analyses on earlier stages. Comparing differentiated cells in 
BM, spleen and PBL of tumour bearing NeuT mice, an increase of total CD11b+ 
cells and of CD11b+Gr1highLy6Cl0W cells together with a reduction of B220+ cells 
was observed in comparison to wt mice. This phenomenon of myeloid cell 
expansion and B cell contraction was observed not only in the BM but also in 
spleen and PBL of the same animals, suggesting a peripheral accrual of myeloid 
populations expanded in the BM (Figure 17A-C).
Considering that the cellular components in BM are strictly regulated, an 
expansion of a subset should reflect the contraction of another one, in order to 
maintain the same total amount of cells. For this reason the contraction of B220+ B 
cells could simply be the consequence of the expansion of CD11b+ myeloid cells. 
Nevertheless, the absolute number of B220+ B cells in 24 weeks old NeuT mice 
was deeply contracted and not balanced by the enhanced number of CD11b+ 
cells, likely suggesting that the observed B cell reduction was an independent 
phenomenon and not only a balance for CD11b+ cell expansion (Figure 17D).
Also, the analysis of progenitor cells (GMP, CMP and MEP) in the BM of NeuT 
mice showed that at the late time point, MEP fraction was reduced while GMP 
subset was significantly expanded, confirming the boost in myelopoiesis observed 
in differentiated immune cell populations (Figure 17E). In addition, the spleen of
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tumour-bearing mice showed a significant increase in lin'ckit+ cells, suggesting an 
increased extramedullary function of this organ (Figure 17F).
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Figure 1 7 - Evaluation of the different leukocyte subsets in BM, spleen and PBL of 
tumour-bearing NeuT mice by flow cytometry
Analysis of differentiated cells in BM (A), spleen (B) and PBL (C) for B220+ B cells, CD3+ T cells, 
myeloid CD11b+ cells and CD11bLyC/Gr1 subsets in BALB/c and NeuT mice at 24 weeks of age. 
D) Absolute number of B220+ B cells and myeloid CD11b+ cells in BM of BALB/c and NeuT mice at 
24 weeks of age. E) Analysis of progenitors (CMP, GMP, MEP) in BM of BALB/c and NeuT mice at 
24 weeks of age. F) Analysis of lin'ckit+ cells in SPL in BALB/c and NeuT mice at 24 weeks of age. 
NeuT (n=6), BALB/c (n=6).
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In order to assess whether such alterations in the immune compartments 
associated to peripheral neoplasia were limited to the NeuT mammary model or 
could be more generally extended, the analysis of the abovementioned immune 
cell population was performed in two additional spontaneous breast cancer 
models, namely PyMT and huHer2A16 mice.
Considering the difference in the timing of tumour progression in PyMT and 
huHer2A16 mice, 22 and 24 weeks of age were selected, respectively, as 
representative of late time points.
Among differentiated cells, an accumulation of CD11b+, CD11b+Gr1highLy6Cl0W 
cells and a reduction of B220+ and CD3+ cells in the BM of PyMT in comparison to 
healthy mice were found (Figure 18A). Consistently, this result suggested that the 
PyMT carcinogenesis is associated with myeloid granulocytic cell expansion in the 
BM, which is remarkable at advanced stages. These data are in agreement with 
the observations in NeuT tumour-bearing mice, at least for late stages of 
carcinogenesis.
On the other hand, the same analysis in the huHer2A16 model at late time points 
did not show any significant expansion of myeloid cells (Figure 18B).
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Figure 18 -  Evaluation of the different leukocyte subsets in BM of tumour-bearing 
PyMT and huHer2A 16 mice by flow cytometry
A) Analysis of differentiated cells in BM for B220+ B cells, CD3+ T cells, myeloid CD11b+ cells and 
CD11bLyC/Gr1 subsets in B6 and PyMT mice at 22 weeks of age. PyMT (n=7); B6 (n=4).
B) Analysis of differentiated cells in BM for B220+ B cells, CD3+ T cells, myeloid CD11b+ cells and 
CD11bLyC/Gr1 subsets in FVB and huHer2A16 mice at 24 weeks of age. huHer2A16 (n=13); FVB 
(n=7).
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4.2 Slight modifications of immune cell populations characterize 
mice with pre-cancerous lesions
To assess whether the modifications in immune cell compartments observed at 
late time point could also be detected earlier, when no overt invasive carcinoma is 
present, the same analysis was carried out at 6 and 12 weeks of age, which 
correspond to hyperplasia and pre-cancerous in situ lesions, respectively.
FC analysis at 6 weeks did not show significant differences among differentiated 
cells in BM, spleen and PBL in NeuT mice compared with their wt counterpart 
(Figure 19A-C). In the spleen of NeuT mice at 12 weeks of age, an increased 
fraction of immature myeloid cells, belonging to granulocytic CD11b+Gr1highLy6Cl0W 
and monocytic CD11b+Gr1l0WLy6Ch'9h compartments was found, in comparison to 
wt mice. In the circulation of the same mice, data were consistent with findings in 
the spleen. Indeed, an expansion of CD11b+Gr1hlQhLy6Cl0W was observed in NeuT 
mice. Although not statistically significant, at the same time point, in the BM of 
NeuT mice there is a slight reduction of B cell compartment (B220+ cells) and an 
increase of CD11b+ cells in comparison to age-matched wt mice (Figure 19D-F). 
The analysis of progenitor cells, during disease progression, did not show 
statistically significant difference neither in BM nor in spleen of NeuT in 
comparison to wt mice (not shown).
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Figure 19 -  Evaluation of the different leukocyte subsets in BM, spleen and PBL of 
6 and 12 weeks old NeuT mice by flow cytometry
Analysis of differentiated cells at 6 weeks of age in BM (A), PBL (B) and spleen (C) for B220+ B 
cells, CD3+ T cells, myeloid CD11b+ cells and CD11bLy6C/Gr1 subsets of BALB/c (n=11) and 
NeuT (n=12) mice.
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Analysis of differentiated cells at 12 weeks of age in BM (A), PBL (B) and spleen (C) for B220+ B 
cells, CD3+ T cells, myeloid CD11b+ cells and CD11bLyC/Gr1 subsets for BALB/c (n=10) and 
NeuT (n=10) mice.
______________________________Results_____________________________
Considering the timing of breast cancer progression in PyMT and huHer2A16 
models, 6-12 weeks and 6-9 weeks of age have been selected as representatives 
of early stages of progression, respectively. FC analysis on early samples did not 
detect any significant differences for both differentiated and progenitor cells in both 
mouse models (not shown).
4.3 Mice with both advanced and pre-cancerous lesions showed 
significant BM stroma rearrangements
To better characterize modification occurring in immune cell populations during 
breast cancer progression, histopathology analyses have also been performed by 
an expert pathologist, Prof. Claudio Tripodo from the University of Palermo.
At late stage a profound modification in the composition and spatial arrangement 
of the hematopoietic populations between tumour-bearing and wt mice has been 
observed. In particular, as already highlighted by FC analysis, an increase of the 
density of myeloid granulocytic cells with immature morphology has been found in 
BM of tumour bearing mice. This expansion was also associated with a 
displacement of lymphoid and erythroid niches and in the contraction of the 
erythroid pool itself (Figure 20).
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Figure 20 -  Morphological analysis and quantification of immune populations of 
BM parenchyma at 24 weeks in NeuT mice.
A) Absolute number of cells per high power field (HPF) of mekagaryocytes, eosinophils, eryhtroids, 
neutrophils, lymphoid and immature myeloid cells in the BM of BALB/c and NeuT mice at 24 weeks 
of age. B) H&E staining in BM parenchyma of BALB/c and NeuT mice at 24 weeks of age and 
identification of eosinophils (red), eryhtroids (yellow), neutrophils (blue), lymphoid (orange) and 
immature myeloid cells (green).
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Once myeloid expansion at late time points had been confirmed, hematopoietic 
cells count of BM sections have been performed in organs collected from mice 
with pre-cancerous lesions at 6 weeks of age. This analysis showed, in 
comparison to wt mice, a slight increase in morphologically immature myeloid 
precursors and a significant decrease in erythroid precursor clusters (Figure 21 A) 
in line with the variations observed in mice with overt carcinoma. Moreover, an 
increase in neutrophil number also emerged from the analysis.
Notably, histopathology analysis finds concordance with FC sample by sample as 
shown by two representative samples in Figure 21B by the similar increment in 
granulocytic cells in NeuT compared to wt mice.
The difference in the BM became more evident along cancer progression at 12 
weeks of age, as the increase in neutrophils and immature myeloid cells and the 
decrease in erythroid precursor were all proved to be statistically significant 
(Figure 21C-D).
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Figure 21 -  Cell count and morphology of immune populations of BM parenchyma 
at 6 and 12 weeks in NeuT mice.
A) Mean number of cells per high power field (HPF) of mekagaryocytes, eosinophils, eryhtroids, 
neutrophils, lymphoid and immature myeloid cells in the BM of BALB/C and NeuT mice at 6weeks 
of age. B) Counts of cells at single mouse level in BALB/c and NeuT mice at 6 weeks of age and 
representative dot plots of FC analysis (lower panel) showing CD11b+ myeloid subset. C) Mean 
number of cells per high power field (HPF) mekagaryocytes, eosinophils, eryhtroids, neutrophils, 
lymphoid and immature myeloid cells in the BM of BALB/C and NeuT mice at 12 weeks of age. D) 
H&E staining in BM parenchyma of BALB/c and NeuT mice at 12 weeks of age and identification of 
eosinophils (red), eryhtroids (yellow), neutrophils (blue), lymphoid (orange) and immature myeloid 
cells (green).
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In order to confirm the decrease in erythroid progenitors with a different approach, 
we focused on erythroid cells characterisation by FC analysis. The cell surface 
erythroid specific Ter119 antigen in expressed by terminally differentiating 
erythroblasts and, at intermediate levels, at the proerythroblast stage. Conversely, 
the transferrin receptor CD71, although not erythroid specific, is expressed at very 
high levels by early erythroid precursors arid its level decreases with erythroid 
maturation. Using FC, we identified, as described in literature (Socolovsky, Nam et 
al. 2001), 4 distinct cell populations: proerythroblasts in the Ter119medCD71h'9h cell 
population (R1); basophilic erythroblasts as Ter119h,9hCD71h,gh cells (R2); late 
basophilic and polychromatophilic erythroblasts as Ter119highCD71med cells (R3); 
orthochromatophilic erythroblasts in the Ter119highCD71l0W cell population (R4). All 
these subpopulation were gated on B220'CD11b' cells (Figure 22A-B).
In agreement with IHC results, we observed a reduction in erythroid progenitors, in 
particular R1 and R2 subsets, in the BM of NeuT mice versus controls at 12 weeks 
of age. Spleen of the same mice showed a similar trend, although not statistically 
significant (Figure 22C).
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Figure 22 -  Characterisation of erythroid subsets in NeuT mice at 12 weeks of age
A) Schematic view of FC plot for eryhtroid cells maturation: proerythroblasts (R1), basophilic 
erythroblasts (R2), late basophilic and polychromatophilic erythroblasts (R3) and 
orthochromatophilic erythroblasts (R4) gated on B220'CD11b+ cells. B) FC dot plots of erythroid 
cells in the BM of BALB/c and NeuT mice at 12 weeks of age. C) FC analysis of erythroid cells in 
BM (left panel) and spleen (right panel) in BALB/c and NeuT mice at 12 weeks of age. NeuT (n=3); 
BALB/c (n=3).
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Through in situ immunolocalization analyses, we also observed that BM 
mesenchymal cells, which account for less than 5% of whole BM cellularity and 
that are hardly recovered by standard BM processing for FC analysis, underwent a 
significant modification in their density and localization already at 12 weeks. 
Indeed, Nestin+ BM mesenchymal cells expand in the BM osteoblastic (precursor- 
rich) and vascular (mature-cells-rich) niches in NeuT samples at 12 weeks and 
display significant up-regulation of the prototypical chemotactic stromal factor 
CXCL-12 at 12 weeks of age in BM of NeuT in comparison to wt mice.
Consistent with this finding, enrichment in CXCR4-expressing myeloid cells in the 
same BM areas of NeuT samples at 12 weeks was found (Figure 23A). We 
observed therefore a rearrangement in the CXLC12/CXCR4 axis: in particular in wt 
mice CXCR4 was linked to erythroid cells and the axis was preferentially 
expressed in the perivascular area, while in the NeuT parenchyma the axis co­
localized with myeloid cells in the interstitial area of the BM (Figure 23B). Overall, 
the results highlighted that the early modifications occurring in the BM parenchyma 
at premalignant phases of cancer development mainly concern an innate immune 
cell subset, specifically granulocytic myeloid cells, that are enriched at the 
expense of other resident populations, being favoured in their repositioning within 
BM erythroid and lymphoid niches by the CXCL-12/CXCR-4 axis.
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Figure 23 -  Immunolocalization of nestin, CXCL12 and CXCR4 in BM of 12 week 
old NeuT mice
A) Quantitative immunolocalization analysis of nestin, CXCL12 and CXCR4 on BM vascular and 
endosteal niches of BALB/c and NeuT mice at 12 weeks of age. B) IHC analysis of CXCL12 and 
CXCR4 expressing elements in BM of BALB/c and NeuT mice at 12 weeks of age.
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4.4 BM does not replace extramedullary function of the spleen in 
NeuT mice
With the idea of inducing in the BM a stress condition in order to accentuate the 
medullary haematopoiesis, spleen of NeuT mice has been surgically removed at 6 
weeks of age and the BM has been analysed 10 weeks later.
The temporary window between the surgery and the analysis of the BM could 
allow the identification of tumour-progression related modifications with a higher 
magnitude in comparison to situation in which the spleen vicariates, at least in 
part, the BM-induced haematopoiesis. However, results from splenectomised mice 
did not revealed substantial changes in either differentiated or progenitor cells, 
suggesting that BM does not respond significantly in terms of increasing 
haematopoiesis after spleen surgical removal (Figure 24).
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Figure 24 -  Evaulation of leukocyte subsets in BM of splenectomised NeuT and wt 
mice
FC analysis of differentiated cells in BM for B220+ B cells, CD3+ T cells, myeloid CD11b+ cells and 
CD11bLyC/Gr1 subsets in BALB/c and NeuT mice subjected or not to splenectomy at 16 weeks of 
age. Each group n=3.
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4.5 BM of tumour-bearing mice is characterized by immune and 
inflammation-related transcriptional programs
To gain further insight into early cancer-related BM changes at molecular level, we 
performed, in collaboration with the Functional Genomic and Bioinformatic Unit of 
our Institute, GEP on BM samples from the same mice analysed by FC and 
histopathology/IHC.
Firstly we performed a class comparison analysis in order to find which genes
were differentially modulated (FDR < 0.05, Fold Change > 1.5) between NeuT and
wt mice at each time point. No genes were differentially expressed at 6 weeks,
instead, at 12 weeks of age 9 genes were up-regulated in the BM of NeuT mice in
comparison to age-matched wt mice (Atf3, Treml, Tnfaip3, Ccl4, Perl, Wdr92,
Ncf2, Ddit3 and Clec4e). At 24 weeks of age, time point in which we expected
pronounced differences between mice with overt tumours and healthy mice, the
analysis showed 374 genes differentially expressed: 233 genes down-regulated
and 141 genes up-regulated in NeuT samples versus controls (Figure 25A).
Using the computational method GSEA (gene set enrichment analysis), in which
annotated gene sets are collected, is possible to evaluate if a gene set is
correlated with the phenotypic class distinction. The gene set approach has the
advantage of making easier the interpretation of the results by identifying
pathways and processes and by detecting subtle enrichment signals. The primary
result of this analysis is the enrichment score (ES), which reflects the degree to
which a gene is over-represented at the top or bottom of a ranked list of genes,
increasing the statistic when a gene is within the gene set. Data obtained with this
approach confirmed genes such as Atf3 and Tnfaip3 positively enriched (in 5 and
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3 gene sets respectively) in NeuT mice already at 6 weeks of age in comparison to 
wt mice (Figure 25B). Interestingly, genes concerning extracellular matrix and 
stroma remodeling were also positively enriched in tg mice at 6 weeks of age: 
Sparc, Spp1, Cxcr4 and collagen family members (Col1a1, Col4a1, Col6a1, 
Col6a3), supporting the in situ observation of stromal rearrangements preceding 
significant changes in haematopoiesis (Figure 25C).
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Figure 25 -  Differentially expressed genes in BM of NeuT and wt mice at different 
time points and enrichment analysis at 6 weeks of age.
A) Volcano plots of GEP analysis in the BM of NeuT mice in comparison to BALB/c mice at 6, 12 
and 24 weeks of age with up-regulated (red) and down-regulated (green) differentially expressed 
genes. B) Leading edge analysis of GSEA in BM of NeuT mice at 6 weeks of age. C) Gene sets 
enriched in the BM of NeuT mice at 6 weeks of age and presence of ECM and stroma-related 
genes into each gene sets.
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As expected from class comparison analysis, the major contribution in terms of 
genes differentially expressed is provided by late time point samples and the up- 
and down-regulated genes were used to build a “late BM gene signature” in order 
to be applied to earlier time points and to validation cohorts. Gene Ontology 
analysis was applied to the up- and down-regulated gene sets of the signature and 
the top 10 biological process domains (FDR < 0.05) were selected as 
representative of the modulated BM transcriptional programs. Among the up- 
regulated genes in NeuT mice we found enrichment for innate immune response 
and inflammatory response programs (Figure 26A). Down-regulated genes, on the 
other hand, included adaptive immune response and B cell receptor signalling 
pathway, in agreement with reduction of B cells compartment in the BM of the 
same mice observed by FC (Figure 26B).
Using the results which emerged from the class comparison analysis at 24 weeks 
of age, we decided to take advantage of GSEA approach running the late BM 
signature, considering the down-regulated genes and the up-regulated genes as 
independent gene sets, against 6 and 12 weeks datasets. Interestingly, an inverse 
correlation was found between genes up and down-regulated at 6 weeks indicating 
that BM samples of mice with very early pre-malignant lesions did not share the 
inflammation-related profile proper of overt malignancy (Figure 26C). Importantly, 
at 12 weeks of age, the same type of analysis showed a direct correlation with late 
gene signatures indicating that an inflammatory switch in BM myelopoiesis and a 
decreased in B cell signalling and immune response-related pathways occurred at 
the stage of dysplasia///? situ cancer (Figure 26D). Together the results suggest 
that the BM attempts to correct stroma modification, which begins very early at
110
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transformation stages, and the pronounced differences characterizing the stroma 
of tumour-bearing mice already mark the BM collected at 12 weeks of age.
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Figure 26 -  Late BM gene signature-related processes and their enrichment at 
early time points
A-B) Barplots showing the top 10 significantly enriched Gene Ontology terms (biological process 
domain) in the list of up- (A) and down-regulated (B) genes of the late BM late signature.
C-D) Enrichment score for the late BM gene signature in the GEP data of BM of NeuT mice at 6 (C) 
and 12 (D) weeks of age.
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Furthermore, taking advantage of Cibersort, a recent analytic tool developed by 
Newman and colleagues, which, using gene expression data, provides an 
estimation of the different immune cell types in a mixed human cell population, we 
could estimate the participation of the different immune cell subsets in the BM 
transcriptional programs of NeuT and BALB/c mice at 24 weeks of age. Being 
aware that the Cibersort signature matrix (LM22) is human-based and built 
considering 22 different immune cell subsets with their specific expressed genes, 
a degree of conservancy of specific immune cells signatures is observed, making 
this approach at least in part reliable on mouse settings. Indeed Cibersort analysis 
indicated a contraction of B lymphocytes and an accumulation of neutrophils in 
NeuT in comparison to wt mice (Figure 27), further confirming our 
histopathological analyses revealing a myeloid cell-skewed haematopoiesis and 
FC data supporting B cell pool contraction.
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Figure 27 -  Application of Cibersort tool on BM of NeuT and wt mice at 24 weeks 
of age
Immune cell composition of BM of BALB/c and NeuT mice at 24 weeks of age (left panel) and 
naive B cells and neutrophils-related box plots (right panels). Cibersort tool provides an estimation 
of different immune cell subsets using gene expression data.
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To validate the data obtained from the first GEP profile (discovery set) we 
collected a new cohort (validation set) of NeuT mice together with control siblings, 
at the same time points analysed so far. In order to technically validate the results, 
some BM samples at 24 weeks analysed in the previous GEP have been 
hybridized together with the new cohort of mice at the same age. Sixty-nine 
differentially expressed genes resulted to be in common between discovery and 
validation set at late time point (Figure 28A) and GSEA, using the up- and down- 
regulated genes of the discovery set against the late BM samples of the validation 
set, showed a perfect overlap between the two cohorts underlining the same 
modulation in terms of enriched genes (Figure 28B). In the second GEP, several 
genes were found differentially expressed already at 6 weeks of age: in particular, 
114 genes were down-regulated and 6 genes up-regulated in NeuT mice in 
comparison to wt mice (FDR < 0.05, Fold Change > 1.5). On the other hand, 
unexpectedly, at 12 weeks we did not observe any modulation in the GEP 
between tg and wt mice. At late time point, as expected, we found several 
modulated genes in NeuT versus BALB/c mice. In particular 54 genes were up- 
regulated and 55 genes were down-regulated (Figure28C).
To assess whether the modulations observed in the NeuT mice were specific of 
that model or could have a broader significance, GEP has also been performed on 
different breast cancer models, PyMT and huHer2A16. Results concerning 
huHer2A16 BM samples highlighted two genes differentially expressed between 
transgenic and wt samples already at 9 weeks of age [Defb15: Fold Change = 
1.41, Col6a3: Fold Change = -2.2], considering as relevant genes with a p value <
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0.001. At 12 weeks of age, 62 genes were differentially expressed whereas at late 
time point (24 weeks of age) 50 genes were modulated (Figure 28D).
The same analysis performed on BM of PyMT mice showed 7 genes differentially 
expressed at 6 weeks of age. At 12 weeks of age 3 genes were modulated 
(Cpebl: Fold Change = 1.2, Nudt7: Fold Change = -1.2, Atg3: Fold Change = -1.7) 
while at 24 weeks of age 52 genes were differentially expressed between the two 
classes (Figure28E).
These results suggest that, at early time points during tumourigenesis, BM 
modifications, in terms of gene expression, are specific for the different transgenic 
models.
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Figure 28 -  Gene expression profile on validation set and in NeuT, PyMT and 
huHer2A 16 mice and wt mice
A) Venn diagram of differentially expressed genes in NeuT mice at 24 weeks of age between 
discovery and validation set. B) GSEA of the late BM gene signature in NeuT validation set at 24 
weeks of age. C) Volcano plots of GEP analysis of the validation set in BM of NeuT mice in 
comparison to BALB/c mice at 6, 12 and 24 weeks of age. D) Volcano plots of GEP analysis in BM 
of huHer2A16 (A16) mice in comparison to FVB mice at 9, 12 and 24 weeks of age. E) Volcano 
plots of GEP analysis in BM of PyMT mice in comparison to B6 mice at 6, 12 and 24 weeks of age. 
Differentially expressed genes are represented in the Volcano plots as up-regulated (red) and 
down-regulated (green) dots.
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4.6 BM late signature discriminate tumour-bearing mice from 
healthy mice in NeuT, PyMT and huHer2A16 mice
As previously described genes differentially expressed between NeuT and BALB/c 
mice at 24 weeks of age of the discovery set (first cohort) were used to build a late 
BM gene signature. According to the signature, the samples of validation cohort 
were clustered and an optimal separation between NeuT and BALB/c groups was 
achieved (Figure 29A), which demonstrated that the discrimination between tg and 
wt mice is achievable according to BM gene expression profiles. GSEA, using late 
differentially expressed genes obtained in NeuT model, was also applied to late 
PyMT (Figure 29B) and huHer2A16 (Figure 29C) samples revealing that common 
BM gene expression pathways are enriched (positively or negatively) in all these 
three models upon overt cancer development, despite different driving oncogenes 
and genetic backgrounds.
In addition the late BM gene signatures have been compared with a new cohort of 
mice with first signs of palpable tumours and the results highlighted a good 
correlation with the up- and down-regulated genes (Figure 29D). This confirmed 
that late BM signature is able to distinguish tg from wt mice with both advanced 
cancer and at first signs of palpable tumour.
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Figure 29 -  BM late gene signature discriminates tumour bearing mice from wt 
mice
A) Heatmaps showing the expression pattern of the late BM gene signature on BM of NeuT mice at 
24 weeks of age of the discovery set (left panel) and of the validation set (right panel).
GSEA of the late BM gene signature in PyMT mice at 24 weeks of age (B), in huHER2A16 mice at 
24 weeks of age and in NeuT mice with first sign of palpable tumours (C).
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4.7 Re-classification of early samples on the bases of mammary 
glands severity using 4 histopathoiogical categories and an 
adjusted score
The data obtained from the two cohorts by GEP analyses of the two cohorts 
(discovery and validation set) were discrepant at early time points (6 and 12 weeks 
of age) in terms of differentially expressed genes between NeuT mice and non- 
transgenic siblings. The reason of such discrepancy could stem from the individual 
variability in the onset and extension of nascent lesions within the mammary 
glands of the mice. Indeed, although the first and major driver of tumour 
development in all NeuT mice is the activated rat Neu oncogene, additional 
mutations/alterations are required in the transforming cell to give rise to a full­
blown cancer and these events could differ in the quality and timing from mouse to 
mouse. This could lead to some variability within the model in terms of both 
severity and extension of the disease at specific time points. To test our 
hypothesis, a throughout histopathoiogical analysis was performed by the group of 
Prof. Tripodo on mammary gland samples from NeuT and wt mice at 6 and 12 
weeks of age and the severity of mammary gland tissue changes was graded 
according to an ad-hoc histopathoiogical score based on the assessment of the 
following variables: ductulo-lobular epithelial hyperplasia, epithelial dysplasia, 
carcinomatous transformation, peri-ductal inflammatory infiltration, distant stroma 
inflammatory infiltration, peri-ductal stromal remodeling. For each of the variables 
analysed, both the degree and the extension of changes were scored.
Morphological and histological analyses on mammary glands of NeuT and BALB/c
samples at early time points showed different grade and extension of such
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parenchyma modifications. NeuT mice showed a certain degree of variability in the 
severity of pre-malignant and/or early cancerous lesions with some cases showing 
signs of accelerated progression, i.e. NeuT samples at 6 weeks showing severe 
dysplastic changes and NeuT samples at 12 weeks of age with foci of 
microinvasive carcinoma, while other NeuT cases characterized by a rather 
indolent rate (Figure 30).
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Figure 30 -  Reclassification of BM samples based on mammary gland disease 
severity
Re-classification of BM early samples (6 and 12 weeks) of BALB/c (wt) and NeuT mice on the 
bases of the disease severity (normal, mild/moderate dysplasia, severe dysplasia and early 
carcinoma). Each mouse is described by the identification number, strain and age.
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Based on the above histopathological analyses, we have firstly developed an 
"adjusted score" to re-modulate the two classes taking into account the 
contribution of the grade/extension of dysplasia and of the grade/extension of 
carcinoma, giving a higher contribution to samples with the presence of cancer, 
and not only dysplasia.
Following this consideration, we settled the formula for the adjusted score as = 
(dysplasia grade + dysplasia extension) * [1 +(carcinoma grade * carcinoma 
extension)]. Using this adjusted score, the severity and extension of the lesions in 
NeuT samples of 12 weeks in comparison to non-transgenic siblings in the two 
cohorts are significantly different, being much higher in the first set of samples and 
therefore possibly explaining the lack of gene modulation we have observed at 12 
weeks of age in the second cohort (Figure 31 A).
Since we observed a considerable degree of individual variability in the onset and 
extension of nascent lesions within the mammary glands of animals, we have re­
classified all BM samples from early time points on the basis of the degree of 
epithelial dysplasia, independently from age or genotype of mice. We sorted early 
samples into 4 different histopathological categories with increasing severity: 
normal (no dysplasia), mild or moderate dysplasia (dysplasia score: 1 or 2 
respectively), severe dysplasia (dysplasia score: 3) and early carcinoma 
(carcinoma in situ/microinvasive carcinoma). This allowed us to compare, with a 
higher resolving power, these classes in order to identify which tissue transition 
had the major role in terms of differentially expressed transcripts in the BM. Class 
comparison analysis between early carcinoma and normal tissue showed that 18 
genes are differentially modulated, 12 up-regulated and 6 down-regulated.
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Notably, some of them, such as Atf3 and Tnfaip3 had been already identified as 
differentially expressed in NeuT and BALB/c mice according to the discovery data 
set at 12 weeks of age (Figure 31B).
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Figure 31 -  Application of the adjusted score on early mammary glands and 
differentially expressed genes in the BM of re-classified samples
A) Comparison between BALB/c and NeuT samples of the discovery and validation set based on 
the assessment of adjusted score. B) Ranked genes differentially expressed and relative Fold 
Change in the comparison between mice with early carcinoma and mice with normal tissue.
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4.8 BM late signature is able to distinguish mice with
normal/mild dysplasia in their mammary glands from those 
with severe dysplasia or early carcinomas
Unsupervised clustering analysis, using the late BM gene signature, considering 
genes with Fold Change > 2, on early samples (only 6 and 12 week time points), 
showed two clusters, clearly distinguishable in the dendrogram (Figure 32). These 
two clusters very efficiently separate early BM samples of mice that have 
normal/mild dysplasia in their mammary glands from those with severe 
dysplasia/early carcinomas. Notably, even if no differences in transcripts have 
been observed with class comparison analysis between NeuT and BALB/c mice at 
6 weeks, the late BM gene signature is able to clearly distinguish NeuT from 
BALB/c samples at this very early time point.
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Figure 32 -  Unsupervised clustering analysis using BM late signature on early 
samples
BM late gene signature (inclusion of genes differentially expressed with a Ifold changel >2) on the 
early samples is able to distinguish mice with normal/mold dysplasia in their mammary glands from 
those with severe dysplasia or early carcinomas.
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4.9 BM and plasma of NeuT mice display up-regulated 
microRNAs
To investigate the signals potentially responsible for the induction of early BM 
changes, microRNA analysis has been performed firstly on the same BM samples 
of the first GEP and then on plasma samples from the same mice. A comparison 
between BM of NeuT and wt mice at each time point revealed differences only at 
24 weeks of age, whereas at early stages of progression the analysis did not show 
any statistically significant differences between the groups (Figure 33A). At the late 
time point (24 weeks of age), 21 microRNAs were differentially modulated 
according to a false discovery rate (FDR) < 0.05 and to a Fold Change > 1.15. 
Among these microRNAs 14 were up-regulated and 9 were down-regulated in 
NeuT mice in comparison to control mice. The most up-regulated microRNAs are 
mmu-miR-21a-5p and mmu-miR-146b-5p (Fold Change = 1.66 and 1.31 
respectively). Some of the differentially expressed microRNAs have been already 
described to have a role in tumour settings and in inflammation processes.
The plasma from the same NeuT and wt mice of the first cohort, has been profiled 
for circulating microRNAs. In order to avoid the possibility that some microRNAs, 
being released after lysis of erythrocytes, could potentially impact the result, we 
settled up an experimental study to takes into account the issue of haemolysed 
samples. To this aim, we included in the case series a group of NeuT samples and 
related controls in which we experimentally forced or not the haemolysis in order to 
evaluate the microRNAs differentially expressed between strongly haemolysed 
samples and non-haemolysed samples. Class comparison between the two
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groups of plasma samples identified significant microRNAs up-regulated due to 
haemolysis, some of which are already known from the literature.
After haemolysis-related microRNAs exclusion, the class comparison analysis of 
circulating microRNAs performed on plasma samples of NeuT and BALB/c mice 
collected at early and late time points showed 28 up-regulated microRNAs at 12 
weeks of age and 80 up-regulated microRNAs at 24 weeks of age in comparison 
to wt mice (Figure 33C). No down-regulated microRNAs emerged to be 
differentially expressed between NeuT and BALB/c plasma samples.
Importantly, among the predicted targets of up-regulated circulating microRNAs 
were found some the down-regulated genes in the BM of NeuT mice. In particular 
some of these genes, as reported above, are related to B cell signaling pathway 
and, in this line, some of circulating microRNAs have among their predicted targets 
B cell-related genes.
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Figure 33 -  BM and plasma differentially expressed microRNAs in NeuT and wt 
mice at different time points
A) Volcano plots of microRNAs profile in the BM of NeuT in comparison to BALB/c mice at 6, 12 
and 24 weeks of age. B) Volcano plots of circulating microRNas profile in the comparison between 
NeuT and BALB/c mice at 6, 12 and 24 weeks of age and Venn diagram of differentially expressed 
microRNAs between 12 and 24 week samples. Differentially expressed microRNAs are 
represented in the Volcano plots as up-regulated (red) and down-regulated (green) dots.
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4.10 Atf3 is up-regulated in the BM myeloid/macrophages and in 
mammary glands of mice with early carcinomas
Among the genes more significantly up-regulated in the BM of NeuT mice with 
early cancer in comparison to wt mice and related with the inflammatory signature, 
the transcription factor Atf3 has been further validated by qRT-PCR on BM of 
NeuT mice at 12 weeks in comparison to BM samples of age-matched wt mice 
(Figure 34A). This modulation was confirmed in mice belonging to the first cohort, 
in which early cancers have been assessed, but not in the second cohort of mice 
in which lower disease severity have been observed in their mammary glands. 
Being rapidly up-regulated in immune cells upon perturbation of homeostasis by 
various signals, Atf3 is an important regulator of immune response and cancer 
progression. The emerging link between CXCL12 and Atf3 in the ECM (Buganim, 
Madar et al. 2011) prompted us to further analyse this gene and the presence of 
the protein in the bone marrow tissue. Indeed, in situ immunohistochemical 
analysis confirmed Atf3 modulation in the granulocytic myeloid cells/macrophages 
of BM samples from 12 and 24 weeks transgenic mice in comparison to matched 
controls (Figure 34C). This result further confirmed our hypothesis of specific 
myeloid subsets undergoing expansion and re-localization within BM stromal 
niches upon sensing of “danger”-related signals from incipient malignancies.
The presence of Atf3 protein was also assessed in the mammary glands with early 
lesions in comparison to normal tissue. Interestingly, its expression was found to 
be more abundant in samples with early carcinoma and associated to 
myeloid/macrophage cells, in concordance with the expression in the BM 
parenchyma of mice with similar primary lesions (Figure 34D).
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To assess whether Atf3 was also up-regulated in other breast cancer models, we 
evaluated the expression of this gene on BM from PyMT mice of 12 and 24 weeks 
of age and on BM from huHer2A16 mice of 9 and 24 weeks. Results obtained for 
both early and late time points, differently from the data obtained in the NeuT 
model, did not show any modulation in the expression between tg and wt mice and 
the overall level of expression in both models was much lower than in NeuT 
samples (Figure 34B).
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Figure 34 -  Evaluation of Atf3 expression on BM and mammary glands (MMG) of 
NeuT mice and in BM of PyMT and huHer2A16 mice
A) Atf3 relative expression by qRT-PCR between validation (first cohort) set and discovery set 
(second cohort) in the BM of BALB/c and NeuT mice at 12 weeks of age. B) Atf3 relative 
expression in the BM of NeuT, PyMT, huHER2A16 (D16) and related controls (BALB/c, B6 and 
FVB) at 12 weeks of age. C) IHC for Atf3 in BM parenchyma of BALB/c and NeuT mice at 12 
weeks of age. Images are representative of the discovery set. D) IHC for Atf3 on mammary glands 
tissue (MMG) collected form BALB/c and NeuT mice at 12 weeks of age in the discovery set.
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4.11 Effects of Atf3 overexpression in engineered macrophage 
ceil lines and in BM progenitor cells
The expression of Atf3 has been evaluated by WB and qRT-PCR upon infection of 
different macrophage cell lines (J774, RAW and MT2) with lentivector that carrying 
Atf3 under the control of the myeloid specific promoter CD68 (Figure 35A). All 
infected macrophage cell lines expressed a higher mRNA amount of Atf3 in 
comparison to wt counterparts although at different levels (Figure 35B). This result 
could be explained by the different expression of CD68 in the three cell lines, that 
was higher in J774 cells in comparison to RAW and MT2 cell lines (Figure 35C). 
The expression of some Atf3 target genes such as MMP-9 and IL-6 have been 
evaluated in this macrophage cell line. As expected infected macrophages, 
overexpressing Atf3 (Figure 35D), have shown to modulate also some of Atf3- 
related targets. Indeed, MMP-9 is found to be up-regulated in J774CD68Atf3 in 
comparison to wt J774 cell line; and II-6 is found down-regulated in tg 
macrophages (Figure 35E).
137
Results
A r_
E M U RRE cPPT mATF3 ANGFRw p re  ■
p ro m o te r  d e le tio n
|CD68s
IVS-1 n r
v \\o \o N ^ ,p \o N a \< 5 \pnV #
£ &  vfcp ^ V 5
c5>o<y'J5r
<y^
■  J774
■  MT2
■  RAW
D J774 J774CD68Atf3
25 KDa -  
15 KDa -
W estern Blot
mmp9
Lfl
□  J774 
Atf3 O  J774CD68Atf3
li-actin
qRT-PCR
il-6
f t
Aiexa Fioor438-H. CD68
Figure 35 -  Overexpression of Atf3 in macrophage cell lines by means of lentiviral 
infection
A) Schematic representation of pRRLsinCD68ATF3.WprePGKNGFR lentiviral vector. B) Atf3 
relative expression of normal J774, RAW and MT2 macrophage cell lines or infected with lentivirus 
encoding for Atf3 at different MOI. C) FC analysis for CD68 in normal J774, RAW and MT2 
macrophage cell lines. D) Atf3 protein quantification by Western blot analysis in normal J774 and 
infected J774CD68Atf3 cell line and relative quantification of Atf3 by Western blot and qRT-PCR. 
E) mmp9 and il-6 relative expression by qRT-PCR in J774 and J774CD68Atf3 cell line.
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In order to investigate weather Atf3 could have a role in driving the expansion of 
BM hematopoietic progenitors, colony forming unit (CFU) assay has been 
performed in BM-derived lineage negative cells (lin‘) infected or not with Atf3 
expressing vector, namely lin'CD68Atf3 and lin", respectively. The number and 
types of colonies provide information about the frequency and types of progenitors 
present in the original cell population and their ability to proliferate and differentiate 
to specific subsets. After assessing by FC the expression of hNGFR in infected 
cells and selecting, by antibody-conjugated magnetic separation, the positive 
fraction, lin- and lin-CD68Atf3 cells were plated in suitable semi-solid matrix and 
CFUs count has been performed after 8, 11 and 13 days. Interestingly, after 8 
days of culture an increase in CFU-M (colony-forming units-macrophage) was 
observed in CD68Atf3lin‘ cells in comparison to wt counterparts. Such increase 
was maintained at 11 days and was paralleled by an expansion of CFU-G (colony- 
forming unit-granulocyte) in CD68Atf3lin' cells. After 13 days these increments 
became more significant and the total CFU-GM (colony forming unit-granulocyte, 
macrophage) was also increased. This result suggests that the overexpression of 
Atf3 in early BM progenitors could favour the expansion towards 
granulocyte/macrophage progenitors in agreement with the high Atf3 expression 
found in these cell subsets in the BM parenchyma of NeuT mice (Figure 36).
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Figure 36 -  Colony forming unit assay on derived BM lineage negative cells
Cell counts of colony forming unit (CFU) assay of BALB/c derived lin” cells infected or not with 
CD68Atf3 expressing vector. Cell counts were performed at 8, 11 and 13 days on CFU-GM, CFU-G 
and CFU-M by optical microscopy.
140
Discussion
5 Discussion
The study of the tumour microenvironment and of its role in tumour development 
and progression has been mainly focused on local districts directly adjacent to 
primary or metastatic tumours. In this context a variety of cell types, such as 
stromal fibroblasts, endothelial cells and immune cells have been studied to 
understand how they foster tumour growth and dissemination. It is also now clear 
that tumour infiltrating immune cells are recruited from distant sites, primarily the 
BM, and actively contribute to the tumour promoting microenvironment of primary 
and metastatic tumours (Chantrain, Feron et al. 2008)
The main hypothesis of the project was that, during tumour development, starting 
from pre-malignant stages, cells undergoing neoplastic transformation and nearby 
stroma cells undertake a vicious cross-talk with the BM hematopoietic and stromal 
parenchyma. This cross-talk is oriented to the instruction of the BM towards 
tumour-promoting haematopoiesis.
As a tumour recruits from the BM immune cells that in turn contribute to the local 
inflammatory and angiogenic reaction associated to malignant transformation and 
progression (Coussens and Werb 2002) it is conceivable that the BM would 
undergo important alterations during an on going distant transformation, even at 
the very early phases.
Taking advantage of animal models of mammary carcinogenesis, within this study 
we indeed demonstrated that the BM actually represents an early sensor of 
incipient malignant transformation at distant sites.
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To define and characterize in details the features of BM modification associated to 
distant transformation, different experimental methodologies were adopted, which 
included FC analysis on precursor and differentiated hematopoietic populations in 
the BM, spleen and PBL, BM histopathological and immunophenotypical analysis 
of hematopoietic and stromal mesenchymal components, gene profiling of the BM 
and microRNA profiling of BM and plasma samples and histopathology of mouse 
mammary glands. Of note, all of the analyses mentioned above were carried out 
on the same mice in order to maximize the comparability of the results obtained by 
the different methodologies. In addition, this comparative approach could allow 
correlating a precise modification in the transforming tissue to the response 
induced in the BM of the same animal, and potentially to circulating signals that 
can be ideally detected in the peripheral blood.
Firstly, the attention has been addressed to relatively advanced stages of tumour 
progression, namely 24 weeks of age in the spontaneous transgenic NeuT breast 
cancer model that also served as positive reference for the subsequent analyses 
on earlier stages.
In 24 weeks old NeuT tumour-bearing mice a profound modification in the 
composition and spatial arrangement of the hematopoietic populations have been 
identified in comparison to healthy mice, confirming that the BM clearly responds 
to a distant transformation tuning its haematopoiesis.
The accumulation of CD11b+ cells in the tumour microenvironment at overt tumour 
stage and in the periphery (BM, spleen and PBL) of NeuT mice has been 
previously demonstrated by our group (Melani, Chiodoni et al. 2003). We 
confirmed here the FC results that were corroborated by, histological analysis on
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the BM parenchyma where myeloid cells with an immature morphology have been 
detected.
Interestingly, we observed a concomitant and significant reduction of B cells, as 
well as a displacement of lymphoid cells and a reduction in the erythroid pools. 
The contraction of the B cell compartment was not confined to NeuT mice, but was 
also detected in the MMTV-PyMT model.
Accordingly, in the latter model, a complete block in B cell lymphopoiesis, 
dependent on tumour burden, has been recently reported by another group 
(Moreau, Mielnik et al. 2016). In the same model, Casbon et al. showed a skewing 
toward myeloid cell production in BM of mice with progressive disease that was 
paralleled by a decrease in erythropoiesis (Casbon, Reynaud et al. 2015).
At late time point, the integration of the precise quantification of different 
hematopoietic subpopulations achieved by FC analysis with the in situ data of their 
numbers and topographical distribution confirmed the robustness of such 
combined approach.
The modulations observed in differentiated cells reflected the expansion of their 
progenitors; indeed the BM of tumour-bearing mice displayed an increase in GMP 
and a reduction of MEP, phenomena that are consistent with the expansion of 
myeloid fraction and the reduction of erythroid cells, respectively.
The BM modifications occurring in tumour-bearing mice also were confirmed using 
genomic approaches, through GEP and relative analyses on BM cells, which 
allowed an in depth view of the molecular processes involved. Indeed GEP of BM 
from mice with advanced cancers displayed hundreds of genes differentially 
expressed in comparison to wt mice. The top biological processes characterizing
143
_____________________________Discussion____________________________
up-regulated genes in NeuT mice are consistent with innate immune and 
inflammatory response-related programs. Down-regulated genes in these mice 
comprise processes belonging to adaptive immune response, lymphocyte 
differentiation and activation programs and B cell signalling.
Accordingly, the presence of an active inflammatory process is well known to be 
linked to tumour development and it is confirmed by cases in which cancer arose 
from chronic inflammation status (Mantovani, Allavena et al. 2008). In addition, a 
dampening in the immune system response is also reported to be adopted by the 
tumour to grow, evading immunosurveillance (Dunn, Old et al. 2004).
In addition, it has been applied for the first time in a mouse setting the human- 
based analytic tool Cibersort. (Newman, Liu et al. 2015), which confirmed a 
contraction of B lymphocytes and an accumulation of neutrophils in NeuT mice in 
comparison to wt mice, making this tool, at least in part, reliable in mouse settings. 
The lists of up- and down-regulated genes in the BM of NeuT mice were used to 
build a “late BM gene signature”, which was further validated not only in an 
independent cohort of NeuT tumour-bearing mice, but also in two different murine 
breast cancer models, namely the PyMT and the huHER2A16, indicating that BM 
transcriptional changes associated to overt carcinogenesis are shared by different 
mammary tumour models despite distinct driving oncogenes and genetic 
backgrounds.
Starting from these evidences in tumour-bearing mice, the analyses have been 
performed at earlier time points of tumour progression, namely 6 and 12 weeks of 
age. At these stages, the modulation of immune cells analysed by FC followed a 
similar trend although not as significant as the one occurring at later stages. The
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modifications in BM parenchyma through histopathology examinations were more 
evident and consistent with the initial hypothesis. Indeed, an increase in 
neutrophils and myeloid immature cells at the expense of erythroid pools 
characterized the BM of these mice. In this scenario, mesenchymal cells also 
expanded in both osteoblastic and vascular niches and displayed an upregulation 
of CXCL12 expression. Consistent with this change in BM mesenchymal cell 
phenotype was the enrichment in CXCR4-expressing myeloid cells in the same 
BM areas. Overall, these results suggest that the early modifications occurring in 
the BM parenchyma at premalignant phases are mainly related to an innate 
immune cell subset, specifically myeloid cells that are enriched at the expense of 
other resident populations, being favoured in their relocation within BM erythroid 
and lymphoid niches by the CXCL-12/CXCR-4 axis. Accordingly, this axis was 
reported to be crucial in the mobilization of BM-derived cells to the sites of 
transformation (Levesque, Hendy et al. 2003).
GEP analyses at early time points displayed different gene modulation between 
discovery and validation set. Such discrepancy could stem from mouse individual 
variability, in the onset and extension of nascent lesions of NeuT mice. Indeed, 
such variability has been confirmed by in depth histopathological analysis of the 
mammary glands of each mouse of the two cohorts and allowed us to build an ad 
hoc adjusted score based on histopathological parameters to reclassify individuals 
independently from their age. Since the progression to in situ carcinoma was 
identified as a crucial event to be correlated with BM phenotypic and molecular 
changes, the “adjusted score” was built mainly considering the contribution of the 
grade/extension of dysplasia and of grade/extension of early carcinoma.
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Re-classifying the early lesions on 4 histopathological categories (normal, 
mild/moderate dysplasia, severe dysplasia/early carcinoma) allowed analysis of 
BM samples, with a higher resolving power, in order to identify which tissue 
transition has the major role in terms of differentially expressed transcripts in the 
BM. Eighteen genes were found differentially expressed between BM of mice with 
early carcinoma and BM of control mice.
The commonalities in the processes characterizing the BM during early and late 
phases of breast tumour development provides the link between the early 
modification in the transforming tissue and a precise BM transcriptional pattern. In 
fact, the late BM signature very efficiently separates early BM samples of mice that 
have normal/mild dysplasia in their mammary glands from those with severe 
dysplasia/early carcinomas. Notably, even if no differences in transcripts have 
been observed with class comparison analysis between NeuT and BALB/c mice at 
6 weeks, the late BM gene signature is able to clearly distinguish NeuT from 
BALB/c samples at this very early time point.
Even if GEP at 6 weeks does not reveal any statistically significant gene 
differentially expressed, GSEA further supports the hypothesis that BM responds 
very early to a peripheral perturbation undergoing stromal changes. In fact ECM- 
and stroma remodelling-related genes were found enriched in BM from 6-week 
NeuT mice. Recent pieces of evidence suggest an important role of collagens and 
other matricellular proteins in tuning both BM and TME. Indeed, some of these 
genes are described to regulate, in the stroma of breast cancer patients, the 
remodelling of tumour microenvironment by structural organizing the ECM 
components (Triulzi, Casalini et al. 2013). This may suggest that modification in
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ECM proteins and stromal components occurring in the primary tumour could be 
similar to those observed distant organs sensing the tumour development such as 
BM.
In order to identify the signals potentially responsible for the induction of the early 
BM changes associated to incipient neoplasia, analysis of both BM and circulating 
microRNAs was performed and identified, in the BM, at late time point, among the 
mostly up-regulated microRNAs mir-21a-5p and miR-146b-5p, both already 
implicated in breast cancer. Indeed, miR-21 has been shown, in human settings, 
to function as an oncogene and to be overexpressed in breast carcinoma tissues 
mediating cell survival, proliferation, extravasation and metastasis (lorio, Ferracin 
et al. 2005). MiR-146, beside being described to be relevant in innate immunity 
and inflammation, (Taganov, Boldin et al. 2006), was also demonstrated to be 
involved in breast carcinogenesis where it correlates with poor prognosis.
Among microRNAs down modulated in the BM, miR-92 is also involved in breast 
cancer, where its down-regulation is associated with aggressive BC features 
(Smith, Baxter et al. 2015).
The analysis of circulating microRNAs significantly modulated at both late and 
early time points showed several microRNAs as differentially expressed between 
NeuT and wt mice, specifically 28 microRNAs up-regulated at 12 weeks and 80 
microRNAs up-regulated at 24 weeks. Among these microRNAs 14 were in 
common between the two time points. Some of these microRNAs were already 
described in the literature to modulate stroma related proteins (mir-29s, mir-328, 
mir-671) or regulating cell cycle, adipogenesis and proliferation and/or already 
associated with breast cancer features in human settings (Tan, Fu et al. 2016).
147
_____________________________ Discussion___________________________
Importantly, among the predicted targets of up-regulated circulating microRNAs 
were found some the down-regulated genes in the BM of NeuT mice. In particular 
the majority of these genes are related to B cell signalling pathway and, in this line, 
some of circulating microRNAs have among their predicted targets B cell-related 
genes.
Among the most up-regulated genes in the BM of NeuT mice with early 
carcinomas, we focused our attention on Atf3, which was already identified as 
differentially expressed in NeuT and BALB/c mice in the discovery set at 12 weeks 
of age. Its role in cancer has been already described, as it was found highly 
expressed in the stroma of human breast cancers and correlating with poor 
prognosis (Wolford, McConoughey et al. 2013) and associated to CXCL12 
enriched areas in the ECM of human tumours (Buganim, Madar et al. 2011).
In both BM and mammary glands of NeuT mice with early carcinomas a high 
expression of Atf3 was found in myeloid/macrophage cells. Hypothesizing a 
putative role of Atf3 in participating to the process regulating myeloid/macrophage 
mobilization from the BM, we decided to address its role in NeuT tumour 
development and progression by over-expressing it in cells of the myeloid lineage. 
Preliminary data on Atf3-overexpressing macrophages indicate a negative control 
on the production of the pro-inflammatory cytokine IL-6, in line with the situation 
likely occurring in the BM in presence of early carcinomas when inflammatory 
processes and danger-related signals are activated. Furthermore upon over­
expression of Atf3 we observed an induction of MMP9 production, which is known 
to have a crucial role in the expansion and function of MDSCs (Melani, Sangaletti 
et al. 2007). Preliminary data of overexpression of Atf3 in BM progenitor cells
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showed an increased potential in colony formation and in particular in the induction 
of macrophage/myeloid cell subset.
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Figure 37 -  Schematic overview of the cross-communication between an incipient 
mammary tumour and the BM
The presence of an incipient tumour induces a series of modification in the stroma, such as 
modifications in the ECM composition, that are reflected in the variations of circulating microRNAs. 
The BM reacts to these variations with an increase in stress response signals (Atf3 and 
inflammatory processes), a decrease of B cells and an increase in myeloid cell number. This 
adaptation of the BM to the presence of a nascent tumour activates a feedback response 
consisting in the mobilization of myeloid cells in the blood stream and microRNAs that can tune 
tumour growth.
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6 On going studies and future prospective
In light of the role of Atf3 in inflammation and in TME we have also planned to 
assess the biological activity of this protein in NeuT model either by silencing or 
forcing its expression in cells of BM origin. In particular, in order to evaluate the 
effect of such modifications in terms of tumour development and of alteration of the 
BM environment we will transplant Atf3 overexpressing BM progenitor cells into 
irradiated BALB/c and NeuT mice. The transplantation of transduced BM cells into 
lethally irradiated BALB/c recipients will allow assessing whether the 
hematopoietic cell expression of Atf3 is sufficient to establish the BM variations we 
have detected in NeuT-bearing mice in absence of an on going neoplastic 
transformation. On the other hand BM transplantation with engineered BM cells of 
young NeuT recipient mice will define whether the forced expression of Atf3 
specifically in the myeloid compartment is sufficient to modify tumour outcome. 
Moreover, in light of the results obtained by microRNA profile that lead to the 
identification of circulating microRNAs differentially expressed between tumour- 
bearers and wt mice, we will design specific experiments to define the biological 
and functional relevance of some specific microRNAs we have found to be 
particularly relevant in our setting.
In addition, in order to obtain more precise and significant data all the analysis 
performed for microRNA profiles will be re-evaluated on the samples after the re­
classification for the severity of the disease, as performed for GEP data.
Moreover, the differential expression of some of the microRNAs modulated in 
NeuT mice will be checked also in plasma sample of breast cancer patients
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pointing out the possibility that the definition of a mouse-derived microRNA 
signature could be transferred into human breast cancer series.
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